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The cover image is the hand of a child making a stop sign. I want it to symbolize that it 
is time that under-treatment of hypertrophic obstructive cardiomyopathy, in particular 
inadequate treatment of women with this disease, should stop. I hope my thesis will 
contribute towards achieving that goal.
To all Kurdish women who fougth against the Islamic State (IS) for the 
sake of humanity but unfortunately those women are forgotten by the world!

5ABSTRACT
Background: Most studies on risk factors for disease-related mortality in hypertrophic cardiomyopathy 
(HCM) have emanated from specialized tertiary centres which are subject to possible referral bias. About
one quarter of HCM-patients have outfl ow obstruction in the left ventricle, hypertrophic obstructive car-
diomyopathy (HOCM). Myectomy has been recommended as “gold standard” treatment for obstruction 
in American Heart Association (AHA) guidelines from 2011, and short atrio-ventricular delay pacing 
(pacing) is not considered. European Society of Cardiology Guidelines 2014 recommended pacing only 
to patients who are ≥65 years of age with co-morbidities. Therefore, it appeared appropriate to study the 
long-term outcome of patients with HOCM in complete geographical cohort in order to assess risk fac-
tors and survival of different therapies. 
Methods: In Paper I the total cohort of 251 HOCM patients (128 male, 123 female) with a mean follow-
up of 14.4±8.9 years were studied for risk factors for disease-related mortality, and the effect of therapy 
(Conservative = no, or only medical, therapy n=121; pacing n=88; and myectomy n=42). In Paper II and 
IV we have compared the effect of pacing and myectomy on mortality (Paper II), and by a case-control 
methodology compared the complications and cost-effectiveness of those two methods (Paper IV). In 
Paper III we have studied the relationship between sex and risk-factors for disease-related death.
Results: Paper I: There were 65 disease-related deaths. Risk-factors for disease-related death on multi-
variate Cox hazard regression were: female sex (p=0.005), age at diagnosis (p<0.001), outfl ow gradient
≥50 mm Hg at diagnosis (p=0.036) and at follow-up (p=0.001). Sudden cardiac death caused 17%, and
heart failure 62%, of disease-related deaths. Late independent predictors of heart failure death were: 
female sex (p=0.003), outfl ow gradient ≥50 mm Hg at latest follow-up (p=0.032), verapamil/diltiazem 
therapy (p=0.012) and coexisting hypertension (p=0.031). Neither myectomy nor pacing modifi ed sur-
vival, but early and maintained beta-blocker therapy was associated with dose-dependent reduction in 
disease-related death. Beta-blockers were used in 71.3% of patients from diagnosis. Kaplan-Meier sur-
vival curves analyzed in initial dose bands of 0-74, 75-149 and ≥150 mg metoprolol/day showed 10-years 
freedom from disease-related deaths of 83.1%, 90.7% and 97.0%, respectively (p-trend=0.00008). Even 
after successful relief of outfl ow obstruction by intervention, there was survival benefi t of metoprolol 
doses ≥100 mg/day (p=0.01). Paper II: Post-intervention follow-up was 12.9±8.7 years and 12.2±5.0 
years, in myectomy and pacing respectively. Both intervention treatments improved New York Heart 
Association (NYHA) class and outfl ow gradients signifi cantly and equally, without survival inferiority 
for pacing (log-rank p=0.43). Survival after diagnosis was not different to that in patients only treated 
conservatively either (p=0.51 pacing/conservative; p=0.39 myectomy/conservative). Re-intervention in 
patients ≥18 years at procedure was needed due to return of the outfl ow gradient in 3.5% of paced vs 
15.6% myectomy patients. Pacing therapy was equally effective in patients aged 13-64 years (n=44), as 
in patients ≥65 years (n=44). Paper III: At diagnosis the median age of females was 11 years higher than 
for men. Females had a higher disease-related mortality than males (log-rank, p=0.003). Excess female 
deaths were caused by chronic heart failure, Hazard ratio (HR) 3.76 [1.85-7.66; p=0.0003] in the age-
matched group, and by myocardial infarctions (p=0.029). There was no sex-bias in respect to interven-
tional procedures, but a lower proportion of females received beta-blocker therapy initially (64% versus 
78%, p=0.011), and in a smaller dose (p=0.006). Verapamil/diltiazem was used in 17.1% females com-
pared to 7.8% of males (p=0.034), and HR for heart failure deaths with verapamil/diltiazem therapy was 
4.20 [1.72- 10.23; p=0.002] in the age-matched groups of both sexes. Paper IV: There were fewer peri-
procedural complications in the pacing-group compared to myectomy-group (3.2% in pacing and 35.5 
p<0.001). During follow-up pacemaker was implanted in 35.5% of myectomy-group for atrioventricular 
block, 9.7% peri-operatively, and 25.8% during late follow-up. Furthermore, the pacing group had a 
superior freedom from all types of re-interventions, 90.3% versus 61.3% in myectomy-group (p=0.003). 
Pacing patients had a signifi cant shorter in-hospital stay and costs compared to myectomy.
Conclusions: 1) Heart failure was a dominant cause of death in this unselected geographical cohort of 
HOCM patients. Independent risk factors for disease, and specifi cally heart failure-related deaths, were
female sex, age and persisting LVOT-obstruction. 2) Beta-blocker therapy aiming for doses of at least 
150 mg/day metoprolol equivalents would be benefi cial even in asymptomatic LVOT-obstruction. 
3) Short atrio-ventricular delay pacing as a simple, cost-effective procedure with low rate of perioperative
complications, and a low need for later re-interventions, was not inferior to myectomy in the relief of 
LVOTO and should thus be considered a valid option to treat patients with HOCM. 4) Early recognition
in females, with a more liberal, and earlier, use of adequate treatment to optimize gradient-control and 
diastolic function, might improve the outcome in females with HOCM.
Key Words: Hypertrophic obstructive cardiomyopathy; myectomy; pacing; beta-blocker; survival; sex 
and re-intervention rate.
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ABBREVIATIONS
AV  Atrioventricular
ACE  Angiotensin Converting Enzyme 
AF  Atrial Fibrillation
AHA   American Heart Association 
AL  Amyloidosis
AMP-kinase  Adenosine Monophosphate-Activated Protein Kinase 
ARB  Angiotensin Receptor Blockers 
ASA  Alcohol Septal Ablation
ASH  Asymmetric Septal Hypertrophy 
ATP  Adenosine Triphosphate
bpm  beat per minute
CABG  Coronary Artery Bypass Grafting
CFC   Cardio-Facio-Cutaneous
CMR  Cardiac Magnetic Resonance Imaging (CMRI)
CRT  Cardiac Resynchronization Therapy 
CT  Computed Tomography
DDD  Dual-chamber pace
ECG  Electrocardiogram
EF  Ejection Fraction
ES  End-Stage
ESC  European Society of Cardiologists
FU   Follow-Up
G+P-  Gen positive and Phenotype negative 
HCM   Hypertrophic Cardiomyopathy 
HF  Heart Failure
HOCM  Hypertrophic Obstructive Cardiomyopathy
HR  Hazard Ratio 
ICD  Implantable Cardioverter Defi brillator
IHSS  Idiopathic Hypertrophic Subaortic Stenosis
IQR  Interquartile Range
LA   Left Atrium
LAD  left atrium diameter
LBBB  Left Bundle Branch Block
LGE  Late Gadolinium Enhancement
LV  Left Ventricle
LVAD  Left Ventricular Assist Devices 
LVEDD   Left Ventricle End-Diastolic Diameter
LVEF  Left Ventricular Ejection Fraction
LVH  Left Ventricular Hypertrophy
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LVOT   Left Ventricular Outfl ow Tract 
LVOTO Left Ventricular Outfl ow Obstruction
LVPW   Left Ventricle Posterior Wall 
MELAS  Acronym for a constellation of fi ndings that includes mitochondrial 
myopathy, encephalopathy, lactic acidosis, and stroke like episodes
MERFF Myoclonic epilepsy with ragged red fi bers
MIBG  Metaiodo-Benzyl-Guanidine 
MPATHY  Multicenter Study of Pacing Therapy for Hypertrophic Cardiomy-
opathy 
MRA  Mineralocorticoid Receptor Antagonists
MYBPC3 Myosin-Binding Protein C 3
MYH7   Beta-Myosin Heavy chain 7
MYL3  Myosin Light chain 3 
NYHA   New York Heart Association 
PCI   Percutaneous Coronary Intervention
PICP  Propeptide of type I procollagen C-terminal 
PRKAG2  Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2
Pro-BNP Pro-Brain Natriuretic Peptide
PVC  Premature Ventricular Contraction
RV  Right Ventricular
SAM   Systolic Anterior Movement 
SCD   Sudden Cardiac Death
SD  Standard Deviation
TEE  Transesophageal Echocardiography 
TNNI3  Troponin I3
TNNT2  TroponinT3
TPM1  Tropomyosin alpha-1 chain 
TTE  Transthoracic Echocardiography 
TTR  Transthyretin
VDD  Ventricle sense and pace 
WOR  Wash Out Rate
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INTRODUCTION 
Background at start of project 
Most studies on risk factors for death due to hypertrophic cardiomyopathy (HCM) 
have emanated from specialized tertiary centres subject to possible referral bias to-
ward patients with a malignant family history for Sudden Cardiac Death (SCD).1, 2 
HCM mortality has been studied in geographical cohorts as well3 but with several 
shortcomings such as failure to document details of medical treatment or failure to 
differentiate the type of death (i.e. sudden arrhythmia, failure or embolism-related).3 
Type of mortality is important because risk factors for sudden death and heart failure 
death are different.4 Thus, these existing studies can neither provide information on 
the natural history, nor of treatment effects3 and have many patients “lost to follow-
up”.5 Short atrio-ventricular (AV) delay pacing has been removed from considerations 
as a fi rst choice in the American Heart Association (AHA) guidelines for hypertrophic 
obstructive cardiomyopathy (HOCM) treatment,6 and European Guidelines from the 
European Society of Cardiology (ESC) 2014 recommends pacing only to patients 
who are elderly, at high risk if undergoing septal reduction, or patients who do not 
want to undergo surgery and  have a mild hypertrophy.7 
During my clinical work in the Västra Götaland region I had observed a good effect 
of short AV-delay pacing on left ventricular outfl ow tract (LVOT) gradient and on the 
clinical status of the patients. Therefore, I wished to study the long-term outcome of 
patients with HOCM in an unselected complete geographical cohort with 100% fol-
low-up in order to assess risk factors and possible effect on survival of drug therapy, 
myectomy and pacing for adverse outcome, without possible interference of referral 
bias. 
The historical background of the disease entity hypertrophic cardio- 
myopathy
A Swiss physician with name Théophile Bonet (1620–1689), and a pathologist who 
refi ned Bonet’s work with name John Baptiste Morgagni (1682–1771), were the fi rst 
who described the HCM disease.8 According Coats and Hollman “Bonet fi rst wrote: 
“A coachman died suddenly in his carriage whose heart was larger than that of any 
bullock, another sudden death of a heart far exceeding its natural bulk.” Morgagni 
later recalled another case: “Often troubled with palpitations particularly in the night, 
an oppressive pain in the chest sometimes was afraid of a swooning and at other times 
of suffocation, the circulation of the blood being obstructed from the left ventricle into 
the artery.”8 This should be the fi rst evidence of the recognition of LVOTO in HCM.9 
Laennec (1781–1826) introduced the term hypertrophy, which means increased nutri-
tion [Greek: hyper = over, trophe = nourishment], affecting the left ventricle, right 
ventricle or both, with or without dilatation.8, 10 
Vulpian described HCM, as “idiopathic hypertrophic subaortic stenosis” in 1868, ac-
cording its anatomical abnormality11 followed by comparable reports in 1869 by Liou-
ville and Hallopeau12, 13 in the Medical Gazette of Paris. Brock from England reported 
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a century later three cases of  LVOT hypertrophy and proposed systemic hypertension 
as primary reason.14 The British pathologist Robert Donald Teare in 1958 was cred-
ited as the person who discribed the disease. He reported 8 cases of young patients 
between the ages of 14 and 44 years, 7 of whom died suddenly, and one died six hours 
post-mitral valvotomy. In a supplement to the same article, he described a ninth pa-
tient, who was the brother of one of the patients; both he and his sister had died sud-
denly. This seems to be the fi rst recognition of the familial nature of sudden death as 
part of the HCM. The heart showed asymmetric septal hypertrophy which he named 
“a muscular hamartoma of the heart”. He described the fi rst histological pattern of the 
disease as, “the pathological picture is one of bizarre and disorganized arrangement of 
muscle bundles associated with hypertrophy of individual muscle fi bers and their nu-
clei.”15 “Pseudoaortic stenosis” is another name which was introduced by Bercu et al. 
in 1958, because of similarity to clinical fi ndings and presentation to aortic stenosis. 
In one case they reported post-mortem fi ndings of a patient with clinically diagnosed 
as aortic stenosis and he was referred for aortic valvulotomy. During the operation, 
the surgeon found completely normal aortic valve cusps and diffi culty to explore the 
left ventricle outfl ow tract because it was “too small to admit the surgeon’s fi nger”.16 
Severe myocardial hypertrophy post-mortem was seen in the patient who died shortly 
after surgery.16 
In 1961, Brockenbrough described the increase in gradient after ventricular ectopics 
as a diagnostic means to differntiate HOCM from valvar aortic stenosis.17 In aortic 
stenosis the obstruction is persistent but in HCM, the obstruction in the LVOT is dy-
namic (orifi ce narrows during systole and relaxes during diastole).17 Brockenbrough 
et al. hypothesised that the beat after a PVC give a more forceful contraction, will 
narrow the orifi ce of the LVOT further. They concluded a higher gradient across the 
LVOT post-PVC will be accompanying with a louder murmur, this became known as 
the Brockenbrough-Braunwald-Morrow sign.18 In 1963, Braunwald et al. described 
the non-obstructive form of HCM for fi rst time.19 They found 14 asymptomatic pa-
tients, who even with having left ventricular hypertrophy, a fourth heart sound, sharp 
arterial pulses, and systolic murmur, did not have evidence of LVOTO.19 In 1964 the 
obstructive form of HCM was described as idiopathic hypertrophic subaortic stenosis 
(IHSS) by Eugene Braunwald, Morrow, Pierce and colleagues.20-22
Abbasi et al. in 1972 reported that M-Mode echocardiography may be used to diag-
nose non-obstructive HCM by demonstrating hypertrophy.23 Asymmetric septal hy-
pertrophy or ASH term by Henry and colleagues in 197324 on the basis of the echo-
cardiographic was another progression of different names to HCM. The noninvasive 
hemodynamic assessment and quantitative measurements of the pressure gradient 
across the LVOT using continuous-wave Doppler were validated against the invasive 
measurements obtained in the catheterization laboratory in the late 1980s.25, 26
Hypertrophic cardiomyopathy 
Defi nition
HCM is defi ned by the presence of increased left ventricular (LV) wall thickness, ≥15 
mm in patients and ≥13 mm in fi rst-degree relatives of probands with unequivocal 
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HCM, which is not solely explained by abnormal loading conditions (e.g. valvular 
disease or systemic hypertension). The hypertrophy can be present in any segments of 
LV, as measured by any cardiac imaging technique.7 
The Prevalence
The prevalence of unexplained increase in LV wall thickness has been reported up 
to 0.23% in adults in different populations in the US, Europe, Asia and Africa and is 
similar in different racial groups.7 The prevalence can be as high as 1 in 200 (0.5%) of 
all people when Cardiac magnetic resonance imaging (MRI) is used as diagnostic mo-
dality.27 The prevalence of clinically diagnosed disease in childhood is much lower, 
2.9 per 100 000 in Finland.28 
Aetiology
Mutations in cardiac sarcomere protein genes, an autosomal dominant trait, in adoles-
cents and adults cause 60% of HCM-cases.29, 30 Beta-myosin heavy chain (MYH7) and 
myosin-binding protein C (MYBPC3) mutations explain the majority of cases; less 
usually affected genes are cardiac troponin I and T (TNNI3, TNNT2), tropomyosin 
alpha-1 chain (TPM1) and myosin light chain 3 (MYL3).7 Patients with a sarcomere 
protein mutation present earlier, have a higher prevalence of family history of HCM 
and sudden cardiac death (SCD),30, 31 have more severe hypertrophy, microvascular 
dysfunction and myocardial fi brosis32 with a poorer prognosis than those without an 
mutation. These reports are based on small numbers of patients, with inconsistency 
between studies, and are few by the rarity of individual mutations.33-39 Multiple sar-
comeric protein mutations as compound mutations (5%) tend to present earlier with a 
severe phenotype.40-42 HCM with histology identical to sarcomeric HCM also occurs 
with malformation syndromes (Noonan, LEOPARD, Costello, CFC (cardiofaciocuta-
neous).43, 44
Phenocopies triggered by other genetic disorders occur in 5-10% of adult HCM pa-
tients. These include: inborn errors of metabolism (Glycogen storage disease ex; 
Pompe, Danon, AMP-kinase (PRKAG2), Carnitine disorder, Anderson-Fabry), neu-
romuscular diseases (Friedreich’s ataxi, FHL-1 = four and a half LIM domains protein 
1), and mitochondrial diseases (MELAS = mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes, and MERFF (myoclonic epilepsy with ragged red 
fi bers). Other non-genetic conditions that mimic genetic forms of the disease, for ex-
ample, senile transthyretin (TTR) and light chain (AL) amyloidosis can be diagnosed 
in some patients.45, 46 
Pathogenesis of disease progression
The diversity of causal genes and mutations causing a common phenotype of HCM 
suggest that multiple mechanisms of pathogenesis of HCM are perhaps causing a fi nal 
common pathophysiology. The mechanisms have been described in four different sets 
by Marian and Braunwald:  Mutation as primary defect, Molecular Events as second-
ary (Intermediary), Histological as tertiary and Clinical as Quaternary Phenotypes.47 
To facilitate different phases of HCM in patients for clinicians, a framework for sys-
tematic clinical staging of HCM in four stages with special weight on diagnosis, pos-
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sible mechanisms, management challenges, and aims for future investigation has been 
proposed by Olivotto at al .48: these are well-defi ned as non-hypertrophic, classical 
HCM-phenotype, adverse remodeling, and manifest dysfunction.48 See Figure 1 for a 
comprehensive description of all stages (modifi ed from47-49).
Stage I: Non-hypertrophic stage of cardiomyopathy (phenotype negative phase) 
Non-hypertrophic in this stage is a combination of primary defects and secondary 
molecular changes.47 This stage is described by the absence of LV hypertrophy in 
genetically positive individuals, examined during systematic family screenings.48 
A signifi cant minority of genotype-positive individual seems to never develop the 
disease at all and the rest can develop left ventricular (LV) hypertrophy as late as the 
6th or 7th decade due to age-related onset and partial penetrance.6, 50 However, even 
in childhood HCM 53% of cases have sarcomere mutations, in 13% the disease pre-
sented in infancy.51 
In a Dutch study a clinical diagnosis of HCM was made at fi rst cardiological evalu-
ation, in 24% of mutation carriers (Mean age 39.3±17.6), and between fi rst and sec-
ond evaluation (Mean duration; 2.9±1.6 years) the phenotype-positive rate rose to 
44%.52 Age related disease penetrance was diagnosed in 41% of mutations carriers 
and males were more often affected than females (p=0.04).53 In this stage electrocar-
diograph (ECG) abnormalities as Q-waves (18% compared to 3% in controls) and 
repolarization abnormalities (T-wave inversion and ST-segment depression) were sig-
nifi cantly more widespread in mutation carriers than in mutation-negative individu-
als.54 Some echocardiographic abnormalities have been reported at this stage, such as 
decreased LV relaxation, increased systolic contraction, abnormalities of mitral valve, 
and some degrees of left atrial (LA) enlargement.55, 56 Type I collagen precursors, a 
fi brosis marker, were signifi cantly higher in mutation carriers without LV hypertrophy 
and in subjects with overt HCM than in controls (31% and 69% higher, respectively; 
p<0.001).57 58 HCM patients with very mild phenotype may have changed coronary 
microvascular function.59 Myocardial crypts (1-6/patient) were identifi ed by CMR in 
19 of 31 (61%) genotype-positive/phenotype-negative patients.60 As many as 16% 
genotype-positive with negative echocardiography examination appear to have some 
degree of LV hypertrophy on CMR.6 In conclusion nonhypertrophic is not equivalent 
with phenotype-negative.48 
Mechanisms of disease (Stage I) When the fi rst “disease gene” for HCM was identi-
fi ed61, 62 the fi nding led to the concept that mutations in genes encoding cardiac con-
tractile and Z-disk proteins in sarcomere have been credibly shown to cause HCM.43, 63, 64 
The mechanisms of disease in HCM however remain only partly understood. Proposed 
mechanisms include (1) a dominant negative function (i.e. a “poison peptide”, where-
in the mutant gene encodes a protein that interferes with the function of the normal 
allele in a concentration-dependent manner); (2) haplo-insuffi ciency (in MYBPC3) 
(causing inadequate quantity of the normally functioning sarcomere protein which can 
be attributed to cell surveillance mechanisms); (3) impaired myocardial energetics and 
decreased energy reserve64-67 and/or (4) the roll of modifi er genes (as responsible for 
the variation in hypertrophic expressivity) and environmental factors, important in de-
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Figure 1. Pathogensis and treatment of hypertrophic cardiomyopathy.
AM=Annual mortality, EF=Ejection fraction, LV=Left ventricle, LGE=Late gadolinium enhancement, LVv=Left ventricle vol-
ume, SVT=supraventricular tachycardia, PVC=premature ventricular contraction, VT/VF=ventricular tachycardia/fi brillation, 
LVOTO=Left ventricle outfl ow obstruction, ICD=Implantable Cardioverter Defi brillator
Modifi ed from: Ostman-Smith, Clin Sci (Lond), 1981 sep, 3; 265-72, Olivotto et al, Circ Heart Fail. 2012 Jul 1;5(4):535-46, Marian 
et al,  Circ Res. 2017 Sep 15;121(7):749-770 
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termining an “awakening” of the phenotype.48, 67, 68 Diastolic abnormalities in pre-LV hy-
pertrophy in HCM-causing mutations, may be due to adverse effects on cardiomyocyte 
intracellular calcium and energy handling.50, 57 The prognosis in this stage is unclear, 
but apparently favorable, possibly similar to that of the healthy people.6, 48, 69
No evidence-based treatment is available for non-hypertrophic HCM. HCM is a 
phenotype with a heterogeneous genetic substrate where hypertrophy is considered 
a pathophysiologic compensatory response, usually caused by mutations of the sar-
comeric proteins. The results of studies underline that energy conservation within 
the myocyte can be an important therapeutic target to try to prevent progression of 
pathological hypertrophy, and to prevent progressive fi brosis development.65, 70, 71 
There is evidence that noradrenaline acts as a “myocardial hypertrophy hormone”.72 
In animal models non-selective, and beta1-selective, beta-receptor blockers have been 
shown to block the trophic effects of noradrenaline on heart muscle and to block or re-
duce compensatory hypertrophy showing that the effect is mainly mediated via beta1- 
receptors.49, 73, 74 Thus, although HCM is a genetic condition, these results suggest it 
may be possible to modify with beta-blockers the pathophysiological cascade leading 
to increased cardiac muscle hypertrophy. 
Stage II: The “Classic” HCM Phenotype 
“Classic” HCM phenotype is defi ned as fully expressed hypertrophic phenotype and 
hyperdynamic LV (ejection fraction [EF] >65%), in the absence of extensive fi brotic 
changes.48 About 80% of adult HCM patients belong to this stage.75 The distribution 
of LV hypertrophy is usually regional and asymmetrical, typically involving the basal 
septum and anterior wall, but may affect any segment of the LV including the papil-
lary muscles or even the right ventricle.48, 69 Cardiac hypertrophy and other abnor-
malities such as autonomic nervous system abnormalities, atrial remodeling, crypts, 
coronary myocardial bridging, mitral valve abnormalities, subaortic, mid-ventricular 
and right ventricular outfl ow obstruction are presented in this stage.56, 76-80 The classic 
features of HCM are myocardial disarray, microvascular remodeling, and interstitial 
fi brosis at the microscopic level.64, 81 
The left ventricle in “classic” HCM is characterized by small or normal-sized cavity 
and hyper-contractility (EF averaged 71%).48, 75 In this stage with the changes in the 
geometry of LV including septum hypertrophy, apparent mitral valve abnormalities 
and enhanced contractility, dynamic LVOTO occurs in about 70% of HCM patients.69
Diastolic dysfunction is almost always present. Diastolic dysfunction of severe degree 
is less common and generally occurs in patients with severe LVOTO, substantial LV 
hypertrophy and restrictive pathophysiology in the end-stage HCM.59, 69, 75, 82 Late gad-
olinium enhancement (LGE) at CMR is presented between 50-71% of HCM patients 
with “classic” phenotype and occupies  a median of 2-10% of the LV.58, 75, 83 But levels 
of serum C-terminal propeptide of type I procollagen (PICP) were signifi cantly higher 
in HCM patients with overt hypertrophy and patients with gen-positive and phenotype 
negative (G+P-) sarcomeric mutation  than in controls (69% and 31% higher, respec-
tively; p<0.001) which suggesting collagen deposition as a profi brotic marker preced-
ing the advance  of the left ventricular hypertrophy or fi brosis evident on CMR.57
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Mechanisms of disease in “classic” HCM phenotype (Stage II) HCM-causing gen-
mutations trigger a cascade of changes in the myocytes as shown in Figure 1. 
In this stage LV hypertrophy is in response to: 
1: In relation to the question of how non-hypertrophic HCM progresses to hypertrophy 
there is evidence that noradrenaline acts as a “myocardial hypertrophy hormone”72 
and excess ATP use that required to generate isometric tension within the sarcomere 
causes LV hypertrophy.43, 65, 84, 85 Noradrenaline released from cardiac sympathetic 
nerve terminals induce compensatory cardiac hypertrophy in animals49, 86, 87 and those 
results have been confi rmed in biochemical model88 and in myocyte cell culture from 
rats.89, 90 High level of myocardial noradrenaline,91 and increased cardiac arteriovenous 
difference in noradrenaline concentration as a result of impaired noradrenaline neuro-
nal re-uptake and metabolism proves increased noradrenaline exposure of myocytes 
in HCM-patients.92 Furthermore, reduced myocardial adrenoceptor density, related to 
a downregulation secondary to increased myocardial concentration of noradrenaline 
has been observed in HCM-patients.93 
Pace et al. reported a correlation between sympathetic activity and cardiac anatomy 
(i.e. degree of hypertrophy), diastolic function and LVOT-gradient in HCM-patients 
using [123I]-Metaiodo-benzyl-guanidine wash-out rate.94 In animal models non-se-
lective, and beta1-selective, beta-receptor blockers have been shown to block the tro-
phic effects of noradrenaline on heart muscle and to block or reduce compensatory 
hypertrophy showing that the effect is mainly mediated via beta1-receptors.
49, 73, 74 Re-
garding HCM in children and adolescents, retrospective well-matched cohort studies 
showed that beta-blocker dose correlated with a signifi cant reduction in mortality both 
due to reduction in the risk of sudden arrhythmia and to risk of heart failure related 
death.4, 95, 96 In this stage beta-receptor blocker, by reducing rate x pressure product 
which is closely and linearly related to myocyte oxygen consumption, improves the 
myocyte’s energy balance
2: Damage to the mechanisms that turn off contraction at low cytosolic [Ca2+], lead-
ing to inadequate relaxation with diastolic dysfunction as result while increasing en-
ergetic compromise is described as another mechanism.48, 84, 97, 98 Ca2+ sensitization 
signifi cantly changed the shape of ventricular action potentials, causing in shorter 
effective refractory periods, greater beat-to-beat variability of action potential dura-
tions, and increased dispersion of ventricular conduction velocities. It was suggested 
these effects produced an arrhythmogenic substrate, cardiac remodeling and, possibly, 
apoptosis.48, 99 But the link between mutation and hypertrophy has not been estab-
lished.98
3: Sarcomeres and their Z-disk apparatuses act as centers of mechano-sensation/trans-
mission/transduction,100 and changed sarcomere mechanics due to faster movement, 
hypercontractility and impaired relaxation,101 and  irregular sarcomere contractile sta-
tus responsible for the persistent increase in sympathetic stimulation in patients with 
HCM as mentioned above49, 76 may cause LV hypertrophy.
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4:  Genetically regulated remodeling of the small coronary vessels with microvascular dys-
function is a potent long-term predictor of progression to LV function impairment.32, 59, 69
Most patients with “classic” HCM phenotype are clinically stable and may never un-
dergo signifi cant degrees of adverse remodeling or disease progression during their 
life (Figure 1).6, 69 Symptoms can include dyspnea on effort, angina, atypical chest 
pain, syncope, SCD, palpitations and paroxysmal atrial fi brillation (AF).6 Individu-
als with severe LVOTO or restrictive physiology have severe functional limitation.102 
Adult HCM patients have an annual cardiovascular mortality around 1%.6, 69 SCD 
rates are low in this stage of disease, but a subclass of patients remain at high risk and 
should be addressed by appropriate checkup.6, 7 Relief of symptoms is the fi rst step of 
management in this stages as well as relief of LV outfl ow obstruction, prevention of 
SCD and cardiac comorbidity, clinical examination for signs of disease progression 
and control of conventional risk factors such as inactive lifestyle, hypertension, dys-
lipidemia, obesity and diabetes.6, 7 Pharmacological management in this stage consists 
of beta-blockers, calcium channel blockers, disopyramide, and amiodarone for con-
trol of symptoms, LV obstruction, and arrhythmias.6, 7 
Stage III: Adverse Remodeling (Clinical phenotype) 
Adverse remodeling is defi ned48 by the presence of negative structural changes, 
overlaid to the “classic” HCM phenotype, with increasing LV fi brosis and deterio-
rated function (i.e. an LVEF of 50-65%), with relatively well-kept clinical and hemo- 
dynamic stability.48 This seems to represent 15% to 20% of adult HCM patients, a 
smaller percentage of whom will fi nally progress to manifest dysfunction and heart 
failure.69, 75, 103, 104 Adverse changes often occur progressively over years or decades.69, 104, 105 
and may lead to overt dysfunction, advanced heart failure and ventricular arrhythmia 
in a brief span of time at any age, including infancy and adolescence.10, 106, 107 Severe 
HCM progression is particularly more prevalent in patients with complex compound 
sarcomere gene mutation heterozygosity genotypes.42, 64 This transitional stage of dis-
ease progression is based on a combination of several adverse features of ventricular 
remodeling, like reduced LVEF,75, 105 marked atrial dilatation,108 moderate to severe 
diastolic dysfunction,102, 109 moderate areas of LGE on CMR,105 severe microvascular 
dysfunction,59 thinning of the LV walls,104 occurrence of AF110 spontaneous reduction 
or loss of LVOTO,104, 111 and LV apical aneurysms.112 The higher accumulation of these 
changes, the more likely is a transition from a “classic” HCM phenotype to adverse 
transformation.48 In HCM patients with low-normal LVEF values of 50-65% (15% 
of a cohort of 310 consecutive patients), LGE was present in 67%, and constituted a 
median of 5% of the LV mass, and it was 100% in patients with an EF <50%, in whom 
it constituted 29% of the LV volume. In patients with an EF of 66% or more LGE oc-
curred in 44% of cases with a median of 2% of the LV volume 75.  
Mechanisms of disease in Stage III Myocardial fi brosis in this stage is suggested to 
be the long term consequences of microvascular ischemia, leading to myocyte death, 
fi brosis,107, 113 metabolically ineffi cient contractions resulting in  possibly aggravating 
myocyte energy depletion in the long-term,114 triggering apoptosis and collagen depo-
sition42 and consequently impairment of LVEF. The patterns and location of myocar-
dial fi brosis are greatly similar across the spectrum of LVEF values, despite quantita-
tive differences, supporting the opinion of a continuum in the generation of fi brosis.75
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In patients with HCM fi brosis expressed as LGE is associated with an increased prev-
alence of ventricular tachyarrhythmias and sudden death.115-117 This observation is in 
line with the substantial rate of arrhythmia- related death observed in patients entering 
the end-stage phase with remodeling and scarring of the LV.107 Clinically this stage can 
vary from mild to severe manifestations by heart failure symptom without LVOTO, 
impairment of cardiopulmonary exercise test, elevated natriuretic peptides,118 onset of 
atrial fi brillation110 and high risk for SCD.119 
The total cardiac mortality in HCM has been estimated to 3-5 % per year when vari-
ous risk factors were considered.48 In this stage close clinical observation with CMR, 
cardiopulmonary testing, serial proBNP titration and TnT may be benefi cial, possi-
bly allowing for preventive management.105, 120-122 Adequately designed, prospective 
randomized trials to test which therapeutic strategies may have a potential impact on 
HCM progression are lacking. It is reasonable to consider well-timed implementation 
of treatments like angiotensin converting enzyme (ACE) inhibitors, angiotensin re-
ceptor blockers (only in dilated end-stage, not in patients with heart failure and small 
cavity with LVOTO), beta-blockers, diuretics and ICD to prevent SCD.6, 7, 123  
Stage IV: Overt Dysfunction or End-stage (ES) HCM 
In this stage HCM patients have severe functional deterioration of the LV (LVEF 
<50% at rest), extreme degrees of myocardial fi brosis and remodeling with hemo-
dynamic decompensation and severe adverse outcome.48, 106, 107 Patients in this stage 
were younger at diagnosis, had a larger LV cavity, had more severe symptoms, more 
commonly had a family history of ES than other patients with HCM.107 Those patients 
had a complex genotypes with multiple mutations in 13% of ES compared with 5% 
of the negative ES-HCM patients in a cohort of 181 HCM patients with preserved LV 
ejection fraction.124 Progressive LV wall thinning occurs in around 10%-15% of HCM 
patients in tertiary centres, and may be marked and more common in those with severe 
(>3 cm) left ventricle hyperthropy (LVH) at initial evaluation.107, 125
The clinical worsening occurs over nearly 5-6 years. LV dimension changes over time 
with a regression of LV wall thickness about 25% (from 20-15 mm, on average) at a 
rate of 1.0 to 2.0 mm per year, LV end-diastolic cavity dimension increases about 20% 
(from 45-55 mm, on average) at a rate between 1 and 4 mm per year, and a parallel 
increase in end-systolic dimension can be demonstrated. EF may decrease from >70% 
to <45%.104 This subset corresponds with so-called “end-stage” HCM, representing 
about 5%-10% of patients in most cohorts from tertiary centres.48, 107
Two types of changes are observed according to the morpho-functional manifesta-
tions of HCM in this progressive phase:
Hypokinetic-dilated form of ES-HCM, increased volume and spherical remodeling of 
the LV is the character of this phase48 and in rare cases, this variant may be hard to 
differentiate from DCM. The diagnosis of HCM relies either on earlier documenta-
tion of asymmetrical LV hypertrophy or family history of HCM.48, 69, 106, 107 This kind 
of diagnostic dilemma is rarely a problem, as the degree of dilatation in HCM is never 
as manifest as that of DCM, and focal hypertrophy is often present.48 In this stage the 
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LVOTO are absent, but other changes like right ventricle dysfunction and pulmonary 
hypertension are common.6, 42, 106, 107
Hypokinetic-restrictive form of ES-HCM, a small and stiff LV with extreme diastolic 
dysfunction, with mildly or moderately impaired LVEF, resembling primary restrictive 
cardiomyopathy are characteristics of this phase.102, 106, 126, 127 Some degree of remain-
ing asymmetrical hypertrophy is apparent, as a result of progressive fi brous substitu-
tion and thinning; marked bi-atrial dilatation and AF are almost regularly present.59, 127 
The decline in LVEF (<50%), and progression of symptoms are slow processes (mean 
duration 14 years).107
The clinical outcome in this phase is severe, Harris et al. reported 11% mortality rate 
per year and 10% appropriate defi brillator interventions per year in patients awaiting 
donor hearts.107 Kubo et al. reported that the 5-year survival rate from all-cause mor-
tality, cardiac transplantation, or ICD discharge was 56.4%.127 Biagini reported 9.2% 
SCD per year in this patient category.102 On the other hand less than 2% of patients 
have required cardiac transplantation or have died in severe heart failure before the 
age of 50.48 
Many patients can be stabilized by using the heart failure guidelines strategies with 
beta-blockers, low-dose diuretics, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, ICD-implan-
tation and anticoagulation in case of AF and apical aneurysm to prevent cerebrovas-
cular events.6, 7 Cardiac resynchronization therapy (CRT) did not show a useful effect 
in this group of patients.128 Hypokinetic-restrictive subtype heart failure in HCM is 
more common than the dilated type127 with low cardiac output on the basis of restric-
tive fi lling at presentation.102, 106 They are more severe to recognize and treat, as they 
may not benefi t or tolerate from the ordinary heart failure therapies48 or left ventricular 
assist devices (LVAD) because of small cavities and quite well-maintained contractile 
function.129 Early hemodynamic evaluation and oxygen consumption stress testing is 
important to avoid missing a window for transplantation.130, 131
Diagnosis of HCM
HCM is defi ned by the presence of a left ventricular (LV) wall thickness, ≥15 mm in 
patients and ≥13 mm in fi rst-degree relatives of probands with unequivocal HCM, 
which is not solely explained by abnormal loading conditions (e.g. valvular disease 
or systemic hypertension). The hypertrophy can be present in any segments of LV, as 
measured by any cardiac imaging techniques like echocardiography, cardiac magnetic 
resonance imaging (CMR) or computed tomography (CT).7
Lesser degrees of wall thickening (13-14 mm) are presented in genetic and non-genet-
ic disorders. To diagnose HCM in these cases requires evaluation of other signs like 
family history, ECG abnormalities, non-cardiac symptoms and signs, laboratory tests 
and multi-modality cardiac imaging.7 The diagnosis of HCM in children needs an LV 
wall thickness more than two standard deviations greater than the expected mean for 
age and body size (z-score ≥2, where a z-score is defi ned as the number of standard 
deviations from the population mean).132 
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The following features challenge the diagnosis of HCM:
-  Late phase of the disease with a dilated and/or hypokinetic left ventricle and LV 
wall thinning.
- Physiological hypertrophy in individual based on intense athletic exercise.
- Patients with co-existent other pathologies.
- Elderly with isolated basal septal hypertrophy.
Most individuals with HCM have a normal lifespan and are asymptomatic, but some 
develop symptoms, often many years after the presence of ECG or echocardiographic 
sign of LVH. Patients with structural and functional abnormalities can develop a va-
riety of symptoms, which are related to heart failure, or arrhythmias and may include 
fatigue, dyspnea, chest pain, palpitations (supraventricular and ventricular arrhyth-
mias), presyncope or syncope.7 HCM is associated with a wide collection of clinical 
signs and hemodynamic abnormalities. Based on site and extent of cardiac hypertro-
phy, HCM patients can advance one or more of abnormalities like: LVOTO, mitral 
regurgitation, myocardial ischemia, diastolic dysfunction.7
HCM with obstruction
HCM is often associated with muscular LVOTO and then named hypertrophic ob-
structive cardiomyopathy (HOCM). A resting or exercise provoked LVOT gradient is 
present in 70% of patients with HCM133 and is an independent predictor of poor prog-
nosis with higher risk of sudden death,96, 134 impaired functional status, and increased 
risk of heart failure.6, 135
Mechanism of LVOT obstruction 
The identifi cation of factors that contribute to the development of LVOTO was fa-
cilitated by the advent of 2D echocardiography. Subaortic (i.e. LVOT) obstruction in 
HCM is due to systolic anterior motion (SAM) of the mitral valve with anterior leafl et 
approaching or contacting the ventricular septum in mid-systole. This creates me-
chanical impedance to blood fl ow as it exits the heart, resulting in a pressure gradient 
between the LV cavity and the aorta. Increased LV systolic pressures are recorded just 
below the level of the mitral valve leafl et-septal coaptation, while the systolic pres-
sures above this point are similar to those in the aorta. The presence of SAM-septal 
contact at rest or with provocation will produce a pressure gradient of 30 mmHg or 
greater. 
There are multiple morphologic alterations of the LVOT area and mitral valve that 
contribute to the development of SAM-septal contact, including: Narrowed diame-
ter of the LVOT due to increased septal wall thickness, apically positioned papillary 
muscles that tether the mitral valve plane toward the ventricular septum, elongated 
anterior leafl et of the mitral valve.
As high velocity blood is ejected from the LV during systolic, the mitral valve is 
pulled or “dragged” toward the ventricular septum (Venturi effect), creating outfl ow 
tract obstruction.136-138 SAM usually involves only the anterior mitral valve leafl et, but 
the posterior leafl et and chordal structures may also be involved. When SAM of the 
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mitral valve occurs, a gap may appear between the apposition of anterior with pos-
terior mitral leafl et, which often produces posteriorly directed mitral regurgitation.138
The magnitude of LVOT pressure gradient measured at cardiac catheterization cor-
relates well with Doppler velocities and with the duration of SAM-septal contact. For 
this reason, there is usually no reason for patients to undergo catheterization to assess 
outfl ow tract gradients, unless the measurements on echocardiographic assessment 
are ambiguous.139 LVOT obstruction can occur associated with any septal wall thick-
ness. In patients with normal or mildly increased septal wall thickness, the mechanism 
for outfl ow obstruction is usually due to elongated anterior mitral valve leafl et. This 
is clinically relevant since those patients who are symptomatic despite drug therapy 
with elongated mitral valve leafl et should be considered for surgical myectomy with 
limited septal resection with mitral valve repair (i.e. plication), rather than percutane-
ous approach with alcohol septal ablation.140 There is often an area of scarring at the 
site of repetitive SAM mitral-septal contact (contact lesion).141
Some patients with LVOT gradients of ≥50 mmHg have mild or no symptoms. Fac-
tors that aggravate LVOTO may increase or induce symptoms of exercise limitation, 
syncope, and/or ischemic chest pain.142 In contrast to posteriorly directed mitral re-
gurgitation, the presence of a central or anteriorly directed mitral regurgitation jet 
suggests the presence of intrinsic mitral valve disease such as mitral valve prolapse, 
torn chordae, or mitral annular calcifi cation,138 which may have a different jet direc-
tion and should be evaluated further with transesophageal echocardiography (TEE), 
particularly if the patient is a candidate for invasive septal reduction therapy since this 
may require repair of the mitral valve at the time the outfl ow tract gradient is relieved.
Dynamic nature of LVOTO 
Defi ned as an LVOT gradient ≥30 mmHg occurs at rest in about 30% of patients. 
Provocation can induce obstruction in about 40% of patients, in response to condi-
tions increasing LV contractility, decreasing LV afterload, or reducing LV systolic 
volume via a reduction in LV preload. In about 30%, there is no sign of LVOTO at 
rest or provocation.133
A variety of manoeuvres and medications can result in induction/increase of LVOTO 
like manoeuvres that reduce preload (chamber size), decrease afterload, or increase 
LV inotropy. 
•  Dehydration, sudden taken of the upright position, the Valsalva maneuver, amyl 
nitrite inhalation, and certain medications (i.e. diuretics, dihydropyridine calcium 
channel blockers, etc.) can induce reduction of preload.
•  Situations associated with increased inotropy include, exercise, infections with fe-
ver, isoproterenol/dobutamine infusion, or post-extrasystolic potentiation (i.e. in-
creased inotropy after an extrasystolic beat).7
Other HCM variants
In addition to the classic description of HCM with or without LVOTO, a variety of 
other HCM variants exist, some of which are managed quite differently than classic 
HCM. 
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Mid-cavity obstructive HCM 
Mid-ventricular (i.e. mid-cavity) obstruction is an important morphologic variant of 
HCM, which arises from different anatomic and hemodynamic circumstances.80, 143 
The most common HCM morphology associated with mid-cavitary obstruction oc-
curs due to the apposition of septum and lateral wall with a small, hyperdynamic 
cavity. In these patients the intracavitary “gradient” does not usually produce clini-
cally signifi cant symptoms, although beta blockers appear to be the most reasonable 
therapy in symptomatic patients. 
Mid-cavity obstruction in HCM can also be due to the systolic apposition of hypertro-
phied papillary muscle and the lateral wall at the level of the mid-LV, producing two 
distinct LV chambers (i.e. proximal and distal with an “hour glass” shape LV), and 
associated with an LV apical aneurysm of varying size.80 This phenotypic subgroup of 
HCM patients is uncommon, present in approximately 2% of patients with HCM.144 
These patients may have limiting symptoms similar to patients with typical isolated 
LVOT obstruction. Clinical examination reveals the typical signs of dynamic obstruc-
tive HCM (e.g. a systolic murmur that accentuates with exercise or a change to an 
upright posture). The diagnosis is made with echocardiography, left ventriculography, 
or cardiovascular magnetic resonance (CMR).145
Mid-cavity obstruction with LV apical aneurysm 
HCM with mid-ventricular obstruction, affects approximately 10% of HCM pa-
tients.146 HCM with midventricular obstruction and coexisting akinetic or aneurys-
mal (maximum dimension, 10 to 66 mm)112 apical chamber affects even less patients 
(1-3% of all individuals with HCM).146, 147 Patients with midventricular obstruction 
are signifi cantly more expected to develop an apical aneurysm compared to those 
without an intracavitary gradient (28% versus 1.8%, p<0.001).146 This represent a dif-
ferent phenotype than apical HCM with LV hypertrophy confi ned primarily to the 
apex. Those patients are at increased risk of ventricular arrhythmias (including sud-
den cardiac death [SCD]), thromboembolic events, appropriate ICD intervention, and 
advanced heart failure.6, 143, 146, 148 For these reasons, it is important to recognize and 
consider primary prevention ICD and anticoagulation treatment to prevent stroke in 
this unique phenotype of HCM. 
Apical HCM 
In this uncommon morphologic variant of HCM the hypertrophy predominantly in-
volves the apex of the LV.149, 150 These patients may have mid-ventricular obstruction 
without LVOT-gradient.112, 150 The prevalence of apical HCM has been diffi cult to 
quantify, but among patients with HCM apical form were found in 41% in Chinese,151 
15% in Japanese152 and 1-3% in non-Asian patients.112, 152, 153 However, Chikamori et 
al. reported distal pattern of hypertrophy in 13% of Japanese and 11% of Europeans 
HCM patients, suggesting that there may not be signifi cant differences in prevalence 
of apical HCM between Asians and other racial groups.154 Most patients with apical 
HCM present with no or mild symptoms, although presentation with angina, HF, myo-
cardial infarction, AF or ventricular fi brillation has been reported.112, 150 Symptoms are 
often mild, but a minority of patients have refractory symptoms of dyspnea, angina, 
and presyncope or syncope due to diastolic dysfunction and low cardiac output. 
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Typical features of apical HCM include:
•    Audible and palpable fourth heart sound, refl ecting impaired LV relaxation
•    ”Giant” negative T-waves on ECG, particularly in the left precordial leads
•    ”Spade-like” confi guration of the LV cavity at end-diastole on imaging
•    Associated apical wall motion abnormalities which may include hypokinesis and 
aneurysm formation150
The diagnosis of apical HCM can be made with echocardiography, left ventriculogra-
phy, computed tomography, or most accurately with CMR.145
Apical HCM patients are managed in the same way as for most patients with HCM 
with medical therapy. Patients with apical HCM do not have sign of LVOT or mid-
cavity obstruction, septal reduction therapy is not an option. Lethal ventricular ar-
rhythmias have been reported in patients with apical HCM.155, 156 In one study SCD, 
resuscitated cardiac arrest, and/or defi brillator discharge was observed in 6% of pa-
tients with apical HCM during a follow-up of 78 months.157 Risk stratifi cation for 
ventricular tachyarrhythmias and SCD is the same as for other patients with HCM. 
The apical variant has a better prognosis than other forms of HCM. In one series of 
105 patients with apical HCM overall estimated survival was 95% at 15years.150
Right ventricular obstruction 
RV obstruction in HCM is very uncommon. This is usually a result of mid-systolic 
contact of prominent right ventricular muscle bundles located in the RV outfl ow tract 
region. If present, RV obstruction can be a cause of symptoms such as exertional dys-
pnea similar to left-sided obstruction. The approach to treatment is similar to the stan-
dard approach to treatment for patients with HCM and LVOT obstruction. Patients 
who remain symptomatic after a trial of medical therapy with AV nodal blocking 
agents can be considered for surgical intervention to relieve right-sided obstruction, 
usually by resection of accessory RV muscle bundles in the outfl ow tract area.158, 159
Obstructive HCM in elderly patients 
HCM can be diagnosed initially in patients of advanced age as in the Framingham 
Heart Study, among 1862 unrelated individuals, with average age of 60 years, who 
did not have hypertension or aortic valve disease, 3% had unexplained increase in 
LV wall thickness. Sarcomeric contractile protein gene mutations were found in only 
18% of these individuals.160 A sigmoidal confi guration to the basal septum is observed 
with increased frequency in elderly individuals and may occur as part of the cardiac 
remodeling associated with aging.161 In addition, the likelihood of identifying a muta-
tion may be lower in late-onset HCM than in earlier onset HCM.162, 163 Older patients 
are more likely to have comorbidities (e.g. coronary heart disease, aortic stenosis, 
etc.) that may also require treatment. Regardless of the age at diagnosis, patients with 
increased LV wall thickness and LVOT obstruction may develop symptoms. The ap-
proach to the treatment of symptomatic LVOT obstruction is the same regardless of 
age (i.e. initial medical therapy, pacing and followed by septal reduction therapy if 
symptoms persist).7
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Resting and ambulatory electrocardiography in HCM 
The ECG is abnormal in most adult HCM patients and shows a variable mixture of 
LVH, ST- and T-wave abnormalities, and pathological Q-waves, but almost 6% had 
a normal ECG with a less severe phenotypic expression of HCM as showed by lower 
wall thickness, LVOTO, symptom progress, complication rates, and cardiac mortal-
ity as compared with HCM patients with abnormal ECGs.164 The ECG is suggested 
at the fi rst clinic visit in all individuals with known/suspected HCM and should be 
repeated on every occasion if there is a change in symptoms.7 The ECG is also a sensi-
tive - however non-specifi c - early marker of disease in relatives to HCM patients.165 
ECG risk score >5 points is associated with high risk for SCD in adult HCM166 and in 
paediatric HCM-patients.167 
Ambulatory ECG monitoring is recommended at the initial clinical evaluation to as-
sess the risk of SCD and stroke.7 Asymptomatic non-sustained ventricular tachycardia 
(NSVT) occurs in 19.5-31% of adults with HCM.168, 169 Paroxysmal supraventricular 
arrhythmias occur during ambulatory electrocardiographic monitoring in up to 37% 
of patients. SVT occurred more commonly in patients with outfl ow obstruction.169 
Monserrat et al. reported no defi nite relation between the duration, frequency, or rate 
of NSVT runs and prognosis at any age: the odds ratio of sudden death in patients 
≤30 years of age with NSVT was 4.35 (95% CI: 1.54 to 12.28; p=0.006) compared 
with 2.16 (95% CI: 0.82 to 5.69; p=0.1) in patients >30 years of age.168 However, in 
even younger patients Östman-Smith et al. reported a relative risk of 9.1 (3.6-22.8) 
for SCD in patients with NSVT at a mean follow-up of 10.9±9.0 years in  patients age 
<19 years at diagnosis.167
Echocardiography features in HCM 
Echocardiography has a central role in assessment of left ventricular wall thickness, 
latent obstruction, left atrial enlargement, systolic and diastolic function, associated 
abnormalities of the mitral valve and left ventricular outfl ow tract and differential di-
agnosis. In patients with known or suspected HCM it is essential that all LV segments 
from base to apex be examined also in short-axis views, ensuring that the wall thick-
ness is recorded at mitral, mid-LV and apical levels.7
Assessment of left ventricular wall thickness 
Accurate assessment of LV wall thickness can be challenging when hypertrophy is 
confi ned to one or two segments, particularly in the anterolateral wall or the LV apex. 
If a segment is not visualized adequately, LV opacifi cation - using ultrasound contrast 
agents and/or CMR - should be considered.170, 171
Abnormalities of the mitral valve and left ventricular outfl ow tract 
Around one-third of HCM-patients have SAM of the mitral valve leafl ets at rest, that 
results in LVOTO, while another third have latent obstruction, which is only dur-
ing manoeuvres that change LV contractility and loading conditions.133, 172, 173 Pap-
illary muscle abnormalities (hypertrophy, anterior and internal displacement, direct 
insertion into the anterior mitral valve leafl et) and mitral leafl et abnormalities such 
as elongation or accessory tissue are other morphological features that contribute to 
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LVOTO.141, 174 In case of LV cavity gradient, it is important to exclude obstruction that 
is unrelated to SAM, including sub-aortic membranes, mitral valve leafl et abnormali-
ties and mid-cavity obstruction, mainly when interventions to relieve LV outfl ow ob-
struction are considered. Systematic two-dimensional (2D) and Doppler echocardiog-
raphy is suffi cient and in some case in combination with CMR in selected patients.7
Assessment of latent obstruction 
Identifi cation of LVOTO is important in the treatment of symptoms and evaluation of 
SCD risk by 2D and Doppler echocardiography during a Valsalva manoeuvre in the 
sitting and semi-supine position - and then on standing if no gradient is provoked- 
in all patients.175, 176 In symptomatic patients if bedside manoeuvres fail to induce 
LVOTO ≥50 mmHg exercise stress echocardiography is necessary. Pharmacological 
provocation (dobutamine) which is not physiological and can be poorly tolerated is 
not recommended. Nitrates should be reserved for patients who cannot perform physi-
ologically exercise test.177
Left atrial enlargement 
The causes of enlargement of the left atrium (LA) are multifactorial, but the most 
common mechanisms are impaired diastolic function, SAM-related mitral regurgita-
tion and elevated LV fi lling pressures.7 LA size was independently associated with 
SCD/appropriate ICD shock,178, 179 and a predictor to AF and thromboembolism.180 
Assessment of diastolic function 
HCM patients often have diastolic dysfunction. Diastolic function measured by Dop-
pler echocardiographic is infl uenced by loading conditions, age and heart rate. There 
is no single echocardiographic factor that can be used as a diagnostic hallmark of 
diastolic dysfunction of LV. Therefore, an all-inclusive evaluation of diastolic func-
tion - including Doppler myocardial imaging, pulmonary vein fl ow velocities, pul-
monary artery systolic pressure and LA size - is recommended as part of the routine 
assessment of HCM ( Criteria recommended for establishing diastolic dysfunction in 
patients with adult HCM are average E/é ratio (>14), LA volume index (>34 mL/m2), 
pulmonary vein atrial reversal velocity (Ar-A duration ≥30 msec), and peak velocity 
of TR jet by CW Doppler (>2.8 m/sec). The parameters can be useful regardless of the 
presence or absence of dynamic obstruction and MR, except for patients with more 
than moderate MR, in whom only Ar-A duration and peak velocity of TR jet are still 
valid.82 HCM patients with preserved EF and a restrictive LV fi lling pattern [ratio of 
mitral peak velocity of early fi lling (E) to mitral peak velocity of late fi lling (A) ≥2; E-
wave deceleration time ≤150 ms] may be at greater risk for adverse outcome.102, 127, 181 
Systolic function 
EF or fractional shortening is usually normal or increased in HCM patients. However, 
EF is a poor measure of LV systolic performance in HCM.182  Myocardial longitudinal 
velocities and deformation parameters (strain and strain rate), derived from Doppler 
myocardial imaging or speckle tracking techniques, are often impaired despite a nor-
mal EF. These parameters may be abnormal before the development of hypertrophy 
in genetically affected relatives. Myocardial longitudinal deformation is usually par-
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ticularly reduced at the site of thickness.79 At the early phase, longitudinal function 
may be reduced, despite that circumferential contractility, measured for example with 
fractional shortening, may have high or supra-normal values. Longitudinal function 
is of value to differentiate against hypertrophy found in “athlete’s heart” which has 
excellent longitudinal function.
Cardiovascular magnetic resonance features in HCM
Cardiovascular magnetic resonance includes several modalities that provide detailed 
information on anatomy, function, fl ow, perfusion, tissue characteristics and differ-
ential diagnosis in HCM patients.183 184 CMR is superior to transthoracic echocar-
diography (TTE) in establishing the diagnosis of HCM in patients with poor acoustic 
windows and poorly visualized LV - such as the anterolateral wall, the LV apex and 
the right ventricle.171 185 
Treatment options in HCM
Pharmacological treatment in HOCM patients
Beta-Blocker 
Medical therapy is the primary treatment for control of symptoms that usually occur 
as chest pain, dyspnoea, palpitations, or as a combination.7, 186-188 Maximum tolerated 
doses of non-vasodilatory beta-blockers are used as fi rst therapy to reduce heart rate, 
prolong diastole, decrease LVOTO especially during activity, and improve myocardial 
perfusion and oxygen delivery by prolonging diastole.189, 190 A short time double-blind 
randomized placebo control trial of propranolol and another beta-blocker (practolol) 
by Hubner et al. found that a propranolol dosage of 320 mg/day was best to reduce 
symptoms in patients with HCM.191 In 1978 Frank et al. found that to block both the 
chronotrophic and inotrophic effects of beta stimulation (administration of 2.4μg/min 
of isoproterenol) consistently required daily doses of propranolol of 320 mg/day or 
more. The optimal doses for a “complete” beta receptor blocking of propranolol for 
management for HOCM patients in their study was on average 462 mg/day. Time to 
maximal improvement with medical therapy was 1-6 years (average 2.75), suggest-
ing at least a 2 years observation time to see the maximal effect of medical therapy.187 
Bourmayan et al. reported a signifi cant association between high doses of propranolol 
(average 391mg/day) and improvement in the Isovolumic relaxation time (IVRT) in 
HCM patients.192  In childhood HCM beta-blocker therapy is also associated with im-
proved survival95  in a dose-related manner,4, 96 and reduces risk of SCD.167 There are 
no randomized long-time beta-blockade studies on mortality in adult HCM patients 
and at the start of our study, there were no corresponding cohort studies to study the 
effect of beta-blocker dose on survival in adult HCM. Of the registry studies avail-
able, Melacini et al.’s negative study from 2007109 is often cited, but in that study, 
only 26% of patients (77/293; 453 patient years) were treated with beta-blockers at 
an unspecifi ed dose, with a median follow-up 6 years, and they only studied effect on 
sudden cardiac death. The study had only 17 (10%) end-points and lacked statistical 
power to detect a protective effect of beta-blockers because only about 1/4 of the pa-
tients received beta-blockers.
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Lee et al. (2007) found in univariate analysis in a study of 163 patients followed on 
average 5.3 years, of which 40% received beta-blockers, that beta-blocker use (dose 
unspecifi ed) had a signifi cant protective effect with a hazard ratio (HR) of 0.25 [95% 
CI0.08-0.77], p=0.012; the effect did not remain signifi cant in a seven-parameter mul-
tivariate analysis,193 but their statistical power would be insuffi cient. 
Summary of the situation with beta-blocker studies prior to my thesis 
Beta-blocker studies of effi cacy on mortality are too few, with a small number of pa-
tient years, have a short follow-up period, are not randomized and lack information 
on the doses used.109, 193 Because beta-blockers are no longer patent-protected, and 
are inexpensive, drug companies have no interest in funding randomized studies of 
suffi cient duration to see the effect of beta-blockers on mortality in HOCM patients.
Calcium channel blockers 
Verapamil/diltiazem in tolerated doses is recommended for symptomatic HOCM 
patients who are intolerant of, or have contraindications to, beta-blockers, and may 
also be considered for asymptomatic patients to reduce the LVOT gradient.7 There is 
currently no evidence that verapamil/diltiazem improves quality of life or reduces 
the risk of sudden cardiac death or heart failure in HCM patients. In a series of 120 
patients who had received verapamil for HOCM, Epstein et al reported serious side 
effects in about 7% (pulmonary edema in 8 patients with 3 subsequent deaths).194 
Verapamil may rarely lead to vasodilation resulting in an increase in LVOTO and sub-
sequent deterioration of clinical status, and is therefore not recommended in patients 
with severe obstruction or elevated pulmonary arterial pressure.189
Summary Verapamil/diltiazem is still used in patients with HOCM, but the long-term 
effects of treatment on sudden cardiac death and heart failure are unclear.
Disopyramide 
If medical treatment with non-vasodilator beta-blockers or verapamil does not pro-
duce the desired effect on symptoms or gradient, international guidelines recommend 
the addition of disopyramide.6, 7, 195 In the largest disopyramide multi-center study with 
118 patients, Sherrid et al. (2005) showed that two-thirds of HOCM patients treated 
with disopyramide could be managed medically with improvement of symptoms and 
about 50% reduction in LVOT gradient over three years. The incidence of sudden 
death was lower (non-signifi cantly) in disopyramide-treated patients. They concluded 
that the disopyramide treatment did not have pro-arrhythmic effect in HCM patients 
and should be considered before proceeding to surgical myectomy or alternative strat-
egies.195 Class IA antiarrhythmic drugs have negative inotropic effects and can re-
duce both resting and provoked LVOT obstruction. Disopyramide also has benefi cial 
effects on diastolic function.196, 197 Anticholinergic side effects (constipation, urinary 
retention, and dry mouth) from disopyramide can often be managed with chewing 
gum, lactulose or dose adjustment, but in the event of severe problems, Mestinon 
(Pyridostigmine) is a cholinesterase inhibitor with a very favorable safety profi le and 
very infrequent side effects (can cause hypotension) that can be given to reduce side 
effects with often good effect.189 Cibenzolin (not registered in Sweden, available on 
license) has also been used for this indication.198
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Summary Disopyramide studies are few, with few patient years and have short follow-
up times, and one-third of patients have intolerance problems or go to invasive treat-
ment.195
Aggressive management of atrial fi brillation 
AF is the most frequent arrhythmia in HCM patients with a prevalence of 22-32% 
in both tertiary110, 199, 200 and non-referral centres201 with an incidence for de-novo AF 
in a general adult HCM cohort about 2% per year.27, 110, 199, 200, 202, 203 AF is  an inde-
pendent risk factor for cardiovascular death, heart failure, stroke and SCD in HCM-
patients.204-207 Paroxysmal AF is an independent determinant of outcome, including 
the risk of HCM-related death, SCD208 and worsened exercise intolerance.209 The fact 
that paroxysmal AF in HCM patients may be frequently sub-clinical and therefore 
untreated is a major risk factor to adverse outcomes.199, 208 Nevertheless, AF has not 
been classifi ed as a major risk factor for SCD in the current guidelines.6, 7 The mecha-
nism of AF in HCM is complex. Myocardial fi brosis with enhanced ectopy in atrial 
and ventricular myocardium,210 and increased left atrial pressure and dilatation due 
to LV-hypertrophy with reduced LV fi lling properties favour the development of AF. 
In most HCM patients with LVOT obstruction, mitral valve anatomy and function 
(Mitral regurgitation in up to 30%) is altered leading to valve insuffi ciency that further 
enhances the left atrial volume with adverse remodeling.200, 211 Aggressive treatment of 
AF in HCM patients is necessary to avoid complications, and the therapeutic options 
do not differ from those without HCM. Early detection and therapy of AF is essential 
with oral anticoagulation even after one single episode of AF. There are no evidence to 
comparing a rhythm control versus rate control strategy in HCM patients, but sustain-
ing sinus rhythm as long as possible and restoring sinus rhythm as soon as possible is 
benefi cial for both improvement of patients symptoms and hemodynamics.6, 7
-  Rhythm control 
    When hemodynamics are critically impaired urgent cardioversion is indicated.7 Ami-
odarone as the best pharmacological option for rhythm control is recommended.212 
However, amiodarone was associated with increased adverse events in patients with 
severe diastolic dysfunction.213 Disopyramide used for LVOTO has been found safe 
in HCM patients195 and is recommended also for avoiding recurrence of paroxysmal 
AF (combined with beta-blocker).6 Beta-blocker as therapy base7 modulates sympa-
thetic activity, improves ventricular contractility and diastolic dysfunction, reduces 
the LVOT gradient and the incidence of supraventricular and ventricular arrhyth-
mia.212 In one retrospective study including 25 HCM-patients loaded on dofetilide 
for AF-suppression, dofelitide facilitated the management of AF in 21 out of 25 
(84%) patients. However, QTc prolongation requiring drug discontinuation in pa-
tients with HCM was more common (12%) than among patients who did not have 
HCM (7.5%).214 Dofetilide (class III antiarrhythmic) is not available in Europe and 
is not recommended in HCM patients according to guidelines. There are no system-
atic data on the use of dronedarone in HCM patients and it is not recommended in 
HCM.7
-  Ventricular rate control  
    Using beta-blockers and non-dihydropyridine calcium channel antagonists - alone 
or in combination - is recommended to reach a resting heart rate <100 bpm. The suf-
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fi ciency of rate control should be evaluated during exercise. In cases of inadequate 
rate control, AV node ablation and permanent pacing may be considered according 
ESC guidelines, with the exception that CRT-P (CRT with a pacemaker) may be 
considered in patients with  LVEF <50%. In the absence of signifi cant LVOTO, 
digoxin (0.125 mg–0.5 mg o.d.), alone or in combination with beta-blockers, may 
be used to control heart rate in patients with AF and an EF <50%, although evidence 
on its effi cacy in this context are lacking.7
-  Catheter ablation 
    There are few data on catheter ablation for AF in patients with HCM. The technique 
should be recommended in patients without severe left atrial dilatation, who are 
unable to take anti-arrhythmic drugs or are symptomatic despite anti-arrhythmic 
drugs.215 
Management of patients with drug-refractory LVOT obstruction
For symptomatic and drug resistant HOCM patients, surgical treatment with septal 
myectomy21, 216, 217 or short AV-delay pacing218-222 with apical positioning of the pacing 
electrode219, 220, 223 to provide a dysynchrony in the left ventricle, have been used. Since 
1995, alcohol septal ablation (ASA) has also been introduced to reduce the gradient 
through a septal infarction.224  ASA was not a recommended treatment alternative in 
Sweden according to the national guidelines during the study period for my thesis 
project.
Surgical treatment with septal myectomy 
WP Cleland was the fi rst one who performed surgical myectomy at Hammersmith 
Hospital, London 1958.216 The patient, a 42-year-old man, who for six years had 
symptoms of tight chest pain, syncope and dyspnoea on physical exertion. A systolic 
gradient of 60 mmHg was measured between the left ventricle and the brachial artery 
by percutaneous puncture. On suspicion of some form of sub-aortic stenosis it was de-
cided to operate. The pressure measurements on the operating table however showed 
no outfl ow-gradient, Cleland was unwilling to continue, but the joining cardiology 
registrar who had measured the preoperative gradient, advised him to explore. The 
aorta was opened, with a normal anatomy of aortic valve. The surgeon passed his 
fi nger into the left ventricle and an extremely enlarged protruding ventricular septum 
was found. After excision of a part of the muscle a great deal of hypertrophied muscle 
remained. After the operation the gradient were almost unchanged, but patient had 
improvement of symptoms and the result lasted for many years.216 Glenn Morrow pio-
neered surgery in hypertrophic cardiomyopathy with sub-aortic ventriculomyotomy 
after visiting Cleland and Hugh Bentall in London. Morrow performed the procedure 
in his fi rst two cases in 1960, in a 10-year-old schoolboy and a 33-year-old man with 
good result,217 and subsequently in a cohort of highly symptomatic HOCM patients 
(NYHA class III), with improvement of almost three-quarters to NYHA class I and 
the rest in NYHA class II.21 The procedure has been known as the Morrow procedure 
and has been modifi ed over the years to involve resection of larger area of myocar-
dium. With removal of 5-10 g myocardium from basal interventricular septum, LVOT 
gradient is usually reduced.225 Surgical myectomy at tertiary centers has been the gold 
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standard treatment for most patients with severe symptoms since 1964 with a reduc-
tion of LVOT gradient in 90% of patients when performed in expert centres.6, 225-227 
At the time of myectomy concomitant papillary muscle abnormalities, moderate-to-
severe mitral regurgitation and/or signifi cant mitral leafl et elongation may be cor-
rected by surgical procedure.6, 7 Mayo Clinic data with 289 patients with 6.2 years 
of follow-up on average reported a 5, 10 and 15-year survival rate of 98%, 96%, and 
83%, without reporting the patients lost to follow-up or rate of any re-interventions.228 
Similar results have also been reported by Swiss authors, but they also reported 14% 
lost to follow-up in which one did not know if patients were alive.226 In a series of 
52 myectomies in children 14.3% of patients needed an additional cardiac surgery 
re-intervention during a 8.6 year follow-up period.229 Surgical myectomy has a surgi-
cal mortality rate of 0.3-1.1% (per operative or within 30 days of postoperative) and 
complication rate of about 28% reported from US tertiary centers.230 
However, studying audited US national statistics for myectomies for all hospitals per-
forming the procedure, the corresponding fi gures US-wide were 5.9% reported mor-
tality and 30-38% complication rate.231, 232 In a US registry study of 11248 patients 
undergoing septal reduction therapy (56.8% myectomy and 43.2% alcohol septal ab-
lation), it was found that during the entire study period of nine years (2003-2011) 
many centres had low volumes: in 59.9% of institutions only 10 myctomies were 
performed, and in 66.9% only 10 ASA were carried out. An increase in hospital mor-
tality (15.6%, 9.6% and 3.8%; p<0.001), an increased need for permanent pacemaker 
(10.0%, 13.8% and 8.9%; p<0.001) and increased rate of bleeding complications af-
ter myectomy (3.3%, 3.8% and 1.7%; p<0.001), were found in low volume centers 
compared to high volume centers when stratifi ed after the fi rst, second and third ter-
tiles of the hospital volume.233 However, note that even the highest volume tertile 
(four hospitals with 126 myectomy procedures during nine years of study period) had 
substantially higher audited operative mortality, 3.8%, than the self-reported fi gures 
of 0.3-1.1%,233 and similarly the 8.9% rate of pacemaker implantation233 was higher 
than self-reported fi gures from Mayo clinic of 2%.234 One could also observe a low 
incidence of death and kidney failure after ASA in high volume centers compared to 
low volume centers.233
Summary Thus, the few studies of the long-term results selected to motivate myec-
tomy as the gold standard, are non-randomized and from highly specialized tertiary 
centers225 with selected young adult patients under the age of 60 with either many “lost 
to follow-up”,226 or without information on number of patients “lost to follow-up”, or 
of subsequent need for re-interventions.228
Short AV-delay pacing  
Hassenstein and Wolter in 1967 reported on two patients with bradycardia who expe-
rienced reductions of their left ventricular outfl ow gradients with pacemaker stimu-
lation of the right ventricular apex. One of their patients was in a critical condition 
but was dramatically improved and regained consciousness during pacing. They con-
cluded that the increased frequency during pacing caused the gradient reduction due 
to shortened diastolic intervals.218 Somewhat later Rothlin and Morcetti investigated 
34
six patients with HOCM and observed a reduction in the mean LVOT gradient from 
60 to 15 mmHg when the electrode was placed in right ventricular apex. However, 
when the electrode was placed close to the pulmonary artery the gradient increased. 
They concluded that the benefi cial effect of right ventricular apical pacing was due 
to the induced left ventricular block pattern.219  Hassenstein reported on four cases of 
pacing in HOCM patients 1975. P-wave triggered pacemakers were implanted and 
LVOT gradient was decreased by 56% and “subjective complaints inclusively cere-
bral syncope were remarkable decreased”.220 Duck et al. reported (n=23 patients) a 
LVOT-gradient reduction of 44%  (from 71 to 40 mmHg) with right ventricle apex 
pacing during heart catheterization and that this was due to an increased outfl ow tract 
area during pacing. They could show that those reductions were not caused by a de-
crease of the stroke volume, but by an enlargement of the effective opening of the 
outlet.221 In all these reports the pre-excitation of the left ventricle by stimulating 
the right ventricular apex, achieving complete ventricular capture by programming 
a short AV-delay during VDD/DDD stimulation to over-ride intrinsic conduction is 
important.220, 221, 223, 235-237 
Optimization of pacing should focus on three key points: ventricular stimulation 
site, ventricular capture and left AV synchrony.238 Apex as ventricle stimulation site, 
showed by Gadler et al. reduced  LVOT gradient  from 96±33 mmHg to 38±24 mmHg 
in contrast to unchanged gradient with septal pacing.223 Berruezo et al. showed that 
58% of patients with short AV-delay pacing had fusion between intrinsic conduction 
and pace activation resulting in lack of improvement in LVOT gradient or symp-
toms.239 Optimization238 of pacemaker recommended during operation was achieved 
by using temporary pacing in VOO mode at 20 bpm above the patients intrinsic rate 
to ensure RV apical pacing and complete ventricular capture on 12-lead surface ECG. 
LBBB confi guration and left superior axis deviation on paced QRS complexes is the 
sign of RV apical pacing. Widest paced QRS duration defi ned as full capture. Paced 
QRS duration and morphology which obtained during operation will serve as ref-
erence of full ventricular capture during follow-up.238 To obtained optimal left AV 
synchrony for full ventricular capture, short AV-delay during VDD/DDD pacing is 
the best option. AV-delay on the one hand must be short enough to give full capture 
of the LV from the RV apex, but on the other hand long enough to achieve a maximal 
atrial contribution to the LV fi lling as described by Daubert et al.238 The mechanism 
of action of AV sequential pacing is not fully clear but some hypothesis explain the 
benefi cial effects include: (i) negative inotropic effect and reduced hyper contractility 
of the LV, (ii) asynchronous late septal activation and delayed septal thickening, (iii) 
limitation of abnormal mitral valve motion, (iv) interaction with LV fi lling, and (v) 
gradual ventricular remodeling.238 
In 1999 Kappenberger et al. reported on favorable results of temporary short AV-delay 
pacing in drug refractory eighty-three HOCM patients (33 female and 50 male) mean 
age 53 (18-82) years. Patients were included in a prospective study after a pacemaker 
(DDD) implanted. After an initial double-blind crossover phase of 6 months, patients 
were reinvestigated at 12 and 36 months. With pacemaker on the LVOT gradient 
signifi cantly reduced from 72±35 mmHg to 29±24 mmHg (p<0.01). At 1 year the ef-
fect persisted with a resting gradient of 28±24 mmHg, an improvement in functional 
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capacity, quality of life, and a signifi cant improvement in dyspnoea and angina. Only 
patients with reduced initial tolerance had improved in exercise on treadmill. During 
follow-up of 36 months (mean), 65 (79%) patients continued with pacing alone. 222, 240 
Reports of short AV-delay pacing from the USA showed the same good result in drug 
refractory HOCM patients. Fananapazir et al. reported in one study of forty-four con-
secutive patients with drug refractory obstructive HCM-patients who underwent im-
plantation of a DDD pacemaker. Symptoms and exercise durations were improved 
and LVOT gradient reduced signifi cantly (87±43 mmHg to 38±38) notably, all cardio 
active drugs were discontinued in all patients before and after pacing.237 Fananapazir 
et al. reported a following study of  long-term (2.3±0.8 years) results of DDD pacing 
in 84 drug refractory HOCM  patients. They concluded that most of the improvement 
of clinical and hemodynamic indexes occurs during the fi rst few months of DDD pac-
ing, additional improvement is often observed a year later, and DDD pacing reduces 
both resting and provokable LVOT obstruction. Furthermore they observed despite 
the presence of LBBB, DDD pacing reduced LVOTO signifi cantly in all 15 patients 
with LBBB.237, 241 
 
Slade et al. reported the result of short AV-delay pacing (median 65 ms, range 25-125, 
ms) in 56 patients with a follow-up duration of 11 month. The mean (range) LVOT 
gradient before implant was 78 (31) mmHg and at follow-up was 36 (25) mmHg 
giving a reduction of 54%. There was a signifi cant improvement in functional class 
with 23 (50%) patients achieving NYHA class I. Nine patients (17%) showed no im-
provement or one had worsening functional status. There was a small but signifi cant 
(p<0.02) improvement in maximum oxygen uptake in the patients who underwent 
metabolic exercise testing.242
A minor American randomized double-blind cross-over study (Multicenter Study of 
Pacing Therapy for Hypertrophic Cardiomyopathy (MPATHY) of 48 patients signifi -
cantly confi rmed the benefi t of pacing treatment to outfl ow gradient and quality of 
life, but found no signifi cant improvement in exercise ability.3 This study is men-
tioned in the discussion below. Another small non-randomized study compared 20 pa-
tients who, based on patient preference, underwent myectomy and 19 patients treated 
by short AV-delay pacing,243 in this study, signifi cantly better gradient reduction and 
greater improvement in exercise capacity were reported in the myectomy group than 
in the pacing group. The follow-up time in the study, however, was longer for myec-
tomy than patients with pacing therapy, myectomy patients were on average 17 years 
younger, many sick patients undergoing myectomy were not included in the study 
(highly selected patients to myectomy), and in addition patients who underwent DDD 
pacing under study time (1995-1997) were part of a multicenter randomized trial as 
mentioned above (M-PATHY) with a LVOT gradient reduction by 40% in M-PATHY 
study,244 but the same cohort of patients as in M-PATHY in this study had a LVOT gra-
dient reduction by 29%, also a 25% less reduction than in M-PATHY(selection bias). 
All this  may be relevant for their ability to increase exercise capacity and the result of 
this study. These two studies were probably infl uential in that short AV-delay pacing 
was removed from considerations as a fi rst choice in the American Heart Association 
(AHA) guidelines for HOCM treatment.6 
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More recently long-term observational studies with short AV-delay pacing from Eu-
rope have reported good symptom improvement and maintained LVOT gradient re-
duction with pacing. In a study from Spain by Galve et al. in 2010 fi fty drug refractory 
HOCM patients underwent a dual-chamber pacemaker implantation with a follow-
up of 10 years. During follow-up, resting gradients decreased successively (baseline 
86±29 fi nal resting gradient 28±24 mmHg), NYHA class improved, as well as exercise 
tolerance (baseline 281±112 m; 3 months 334±106 m; 1 year 348±78 m; p<0.0001).245 
Lucon et al. reported on 51 drug refractory HOCM patients who underwent implanta-
tion of DDD pacemakers with or without a defi brillator and were followed for 11.5 
years.246 During follow-up, no patient underwent interventional treatment as myec-
tomy or septal alcohol ablation. NYHA functional class decreased signifi cantly and 
the LVOT gradient decreased by a mean of 89% at end of follow-up. The 5- and 10-
year survival rates were 90% and 65%, respectively.246 Thus it appears that benefi t 
of short AV-delay pacing on outfl ow-gradient increases with time, perhaps through 
benefi cial re-modelling. Currently European Guidelines from the European Society 
of Cardiology 2014 recommends pacing to patients who have a high risk if subjected 
to septal reduction, patients who do not want to undergo surgery and those who have a 
mild hypertrophy.7 One observation of relevance is that chronic pacemaker treatment 
on other indications has also been shown to lead to a dilated cardiomyopathy with 
reduced systolic function.247 
Summary Pacing studies have included few (8-84) patients248, 43, 241 and elderly patients 
with short follow-up periods,222, 237 or are without control groups.245, 51, 246, 52
Alcohol septal ablation (ASA) 
ASA has recently been used to a greater extent in Europe as it is alleged that it has an 
effect as good as myectomy7 but there are no randomized studies. ASA has a higher 
frequency of complications in the form of atrio-ventricular blocks requiring perma-
nent pacemaker following the procedure (7-20%)7 compared to myectomy (4%).249 
Re-interventions after ASA for LVOTO occur in about 10%.119, 250 Quintana et al. re-
ported that patients who are referred to myectomy after ASA with insuffi cient relief of 
LVOTO have poorer diastolic function and higher frequency of arrhythmias, a higher 
frequency of postoperative complete heart block and a higher perioperative mortality 
rate of 6.2%.251 As for other treatment options, nothing new has emerged recently.137
Shortcomings of studies dealing withy treatment of obstructive HCM
•   Non-randomized studies, from tertiary centers with referral bias, without any con-
trol group.
•   Short follow-up time, this means that long-term effects of therapy (medication, 
septum reducing treatment and pacing therapy) on the mortality of adult HOCM 
patients are poorly elucidated.
•   Few patients in studies (about 50% of HCM studies have <20 patients in their stud-
ies, 7% have ≥50 patients), this gives low statistical power.
•  Many “lost to follow-up” or unreported data on “lost to follow-up”.
•  Complications and re-interventions are not adequately reported.
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•   As a result of the above, scientifi cally robust studies defi ning best treatments for 
obstructive HCM are lacking.
In order to see the effect of long-term results of various treatments (pharmacotherapy, 
surgery or pacemaker) on outfl ow obstruction in hypertrophic obstructive cardiomy-
opathy on HCM-related deaths, a long-term follow-up study, with 100% complete 
follow-up and without the infl uence of referral bias, is needed. To get enough patient 
years, we have studied a total geographical cohort throughout the Västra Götaland 
region with no loss to follow-up and complete documentation of causes of death, to 
highlight the following issues:
1.  Does the treatment of outfl ow obstruction with surgery have better long-term re-
sults than pacemaker treatment?
2.  What are the risk factors that affect mortality in patients with HOCM in a geo-
graphical cohort?
3.  What are the mortality patterns in a geographical cohort of HOCM patients?
4.  What is the long-term effect of pharmacological treatment on disease-related mor-
tality?
5.  Are there gender differences in mortality among HOCM patients, or is there refer-
ral-bias in the gender distribution to tertiary centers? What might be the factors that 
affect any gender differences?
6.  How do complications, and early and late morbidity, compare after surgical myec-
tomy or pacing therapy in a case-control analysis of matched patients?
7.  Length of stay at hospital and costs related to myectomy compared to pacing ther-
apy in a case-control analysis of matched patients
Our study is about primary HCM, including Noonan spectrum mutations because this 
group of mutations has identical histology. Many physicians fail to recognize mild 
dysmorphology among adult HCM populations. When Jacqueline Noonan visited Bill 
McKenna´s outpatient clinic for HCM in London, she spotted several unrecognized 
Noonan patients (W. McKenna, pers communication), and paediatric cardiologists 
in Västra Götaland have recognized several adult HCM-patients with un-diagnosed 
co-existing Noonan syndrome in contact screening of familial paediatric cases. Thus 
many published HCM-studies will likely include patients with unrecognized Noonan-
syndrome associated HCM. Patients with storage disorders that have secondary HCM 
are not included (Danon, Fabry, Familial amyloidosis, Friedreich ataxia and other 
mitochondrial cardiomyopathies).
Total study cohort
Adult in- and outpatient cardiac care for the 1.6 million inhabitants of West Götaland 
Region is provided by 10 hospitals (Sahlgrenska, Östra, Mölndal, Uddevalla, Troll-
hättan, Skövde, Lidköping, Alingsås, Borås and Kungälv). We searched all hospital 
diagnostic databases (Melior data system) for adult patients attending hospital from 
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January 2002 to December 2013 with ICD diagnostic codes (I42.0, I42.1, I42.2, I42.3 
and I 42.8) relating to a diagnosis of HCM, and reviewed the case notes on site (D.J. 
and I.Ö.S.) to identify those with HCM and outfl ow tract obstruction (HOCM).We 
identifi ed 1142 adult patients, out of whom 251 (22%) patients had obstructive HCM 
with a resting LVOT gradient ≥30 mmHg,7  with an even sex distribution (128 male 
age 51years [IQR=27] and 123 females age 62years [IQR=20]). Syncope occurred in 
25.4% and 15.1% had a family history of SCD. Among total cohort 75.3% reported 
symptoms as reason to search health care, 24.7% did not report any symptoms related 
to HCM (Figure 2A). Co-existing Noonan syndrome was identifi ed in 7 patients (3 
females and 4 males). 
The average NYHA class was 2.2 (±0.73) at diagnosis, Figure 2B.
Transthoracic echocardiogram measurement showed (median [IQR]): septum 19 [6] 
mm, LVEDD 43 [9] mm, LAD 41 [15] mm, LVOT gradient at rest 65 [57] mmHg and 
EF 69% [15]. AF was present in 4% at diagnosis, systemic hypertension in 13.5%, 
diabetes in 5.6%, coronary artery disease in 3.6% and chronic obstructive pulmonary 
disease (COPD) in 6.8%. The maximal septal wall thickness was ≥30 mm in 9 (3.4%) 
of the patients.
Initial medical therapy is shown in Figure 3.
Reasons not to have cardio-protective medication
At diagnosis 74 out of the 251 HOCM-patients (29.5%) did not receive BBL-treat-
ment and for 8 patients data are missing. Calcium blockers – presumably at that time 
considered just equally effective as cardio-protection – were given to 26 patients i.e, 
48 patients did not have cardio-protective medication with either beta-blockers (BBL) 
or calcium channel blockers (CCB). Among the 48 patients without initial cardiopro-
tective medications (BBL or CCB) 57.8% were symptomatic and their median LVOT 
gradient was 65 [IQR 46] mmHg.
 
Among all patients only 4/251 (1.6%) did not tolerate BBL, because of tiredness. 
In  patients who did not receive any BBL at diagnosis we could not fi nd any differ-
ences in age and co-morbidities (hypertension, heart rate, AV-block, QRS duration at 
diagnosis, or presence of COPD or diabetes at diagnosis or at follow-up) compared to 
patients that were treated with BBL. Of patients treated with calcium-blocker at diag-
nosis 27% had COPD compared to 7.3% in BBL group (p=0.0008), otherwise there 
were not any signifi cant differences in age, gender, blood pressure, heartrate, QRS 
duration or diabetes compared to patients with BBL.
Among those treated actively the initial treatment was always pharmacotherapy and 
during the study period 121 of the 251 patients (48.2%) did not receive intervention 
(101 on drug therapy and 20 without drug-therapy). However, 130 required interven-
tions, 88 with short atrioventricular delay pacing and 42 with myectomy. The time 
from diagnosis until intervention for pacing group was 3.4 [6.3] and myectomy group 
4.5 [8.1] years, p=0.20.
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Figure 2. A. Diagnosis according to patients self-reported symp-
toms. B. NYHA class at diagnosis estimated by doctor.
Figure 3. Initial medications.
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Vital status was censored on 28 February 2015. Death certifi cates from the National 
Board of Health and Welfare were obtained to establish causes of death in addition to 
case note review. No patient was lost to follow-up. See Table I, Paper 1, for character-
ization of total cohort at diagnosis.
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AIMS
The aims of the studies were:
Paper I
To assess risk factors for HCM-related mortality in a geographic cohort of patients 
with hypertrophic obstructive cardiomyopathy and any therapeutic effect of pharma-
cotherapy and interventional therapy on survival.
Paper II
To compare long-term results after treatment of left ventricular outfl ow obstruction in 
hypertrophic obstructive cardiomyopathy with myectomy or with short atrio-ventric-
ular delay pacing
Paper III
To assess the impact of female sex on disease-severity and prognosis. Possible sex-
specifi c risk-factors for disease-related mortality are examined in more detail in this 
unselected complete geographical cohort of hypertrophic obstructive cardiomyopathy 
patients. 
Paper IV
To compare short- and long-term morbidity following treatment of left ventricular 
outfl ow-obstruction in hypertrophic obstructive cardiomyopathy by myectomy or by 
short atrio-ventricular delay pacing
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MATERIAL AND METHODS
Paper I
Subjects and Method
In this complete geographical cohort of 251 HOCM patients we reviewed records 
for: clinical data, ECG and echocardiographic fi ndings, presence of proposed risk 
factors and comorbidities, therapy modalities (conservative; with or without medi-
cal therapy but without intervention, n=121, pacing n=88, myectomy n=42) as well 
as recording ICD therapies. The type of all medical therapy used was recorded at, or 
shortly after, diagnosis and at latest follow-up visit. Type and dose of beta-blocker 
and calcium-channel blocker (CCB) therapy were documented. For statistical evalu-
ation, all beta-blocker doses were converted to corresponding doses of metoprolol 
(the beta-blocker most commonly employed: 48.6% metoprolol, 22.7% bisoprolol, 
7.5% propranolol and 6.7% atenolol). The conversion used was metoprolol 100 mg = 
propranolol 80 mg252 = bisoprolol 5 mg = atenolol 50 mg. The mean follow-up time 
was 14.4±8.9 (mean±SD) years. Among the 26 patients with CCB, 3 had diltiazem 
and 23 had verapamil. The dose of diltiazem converted to the same equivalent doses 
of verapamil as both drugs exhibited consistent effi cacy with minimal adverse effects 
in equivalent doses.253
Endpoints The primary endpoint was a composite of total cardiac mortality, heart 
transplantation and fatal embolic stroke of presumed cardiac origin together referred 
to as “disease-related death”, and secondary end-points were heart failure death and 
appropriate shocks from ICD. Other outcome parameters in the total cohort are NYHA 
class, permanent AF, outfl ow gradient measured with Doppler and left ventricular 
wall thickness. NYHA class was assessed by the physician at the initial visit or within 
three months in 222/251 (88.4%) cases, and by analysis of patient records in 29/251 
(11.6%) cases according to NYHA classifi cation criteria.254 
Paper II
Subjects and Method
As mentioned above 203/251 patients were initially tried on medical therapy; 121 
remained in conservative group (16.5% without medications). Of those having in-
suffi cient control of gradients or symptoms, 88 patients were treated with short AV-
delay pacing (19.3% without cardioprotective medication), and 42 patients underwent 
a surgical myectomy (19% without cardioprotective medication). For patients aged 
≥18 years, fi rst-line procedure was determined by the responsible physician and pa-
tient preference. The fi rst choice of intervention for patients <18 years of age was 
myectomy. Thus among the patients in the cohort, we identifi ed 10 patients who had 
myectomy after infancy but <18 years of age, but who at last follow-up were adults 
(n=6) or teenagers (n=4). Furthermore, four patients (all now adults) received pacing 
therapy <18 years of age: in patients aged 13-17 years where an ICD was indicated 
(three primary, one secondary prophylaxis) and the device was used also for short AV-
delay pacing. Two of the four had had unsatisfactory results from a prior myectomy. 
Clinical data, ECG and ultrasound measurements were documented at pre-procedure 
43
examination, and at last follow-up visit, as well as medical therapy and interventional 
procedures during follow-up. 
Cardiac surgery (myectomy) was carried out at the Sahlgrenska University Hospital, 
Gothenburg, and short AV-delay pacing was also undertaken in Uddevalla, Trollhättan 
and Skövde as well as the Sahlgrenska Hospital. 
Dual-chamber permanent pacemakers were implanted in a standardized way with 
fl uoroscopy- and echocardiographic verifi cation that the ventricular electrode tip was 
placed optimally in the apex of the right ventricle. AV-delay was set under ECG-
control to ensure abolition of spontaneous conduction, and then evaluated by echocar-
diography in order to obtain maximal LVOT gradient reduction without deterioration 
of diastolic fi lling.241 Septal myectomy was performed as described by Robbins and 
colleagues.225
Endpoints The primary endpoint was disease-related death (henceforth: ‘cardiac mor-
tality’), in which we included death due to heart failure, arrhythmia, death-certifi cate 
classifi ed sudden deaths, bacterial endocarditis (n=1), fatal strokes in patients with 
AF and due to embolism from a presumed cardiac source, and cardiac transplantation 
that was considered a death equivalent. The secondary endpoint was re-intervention 
for residual LVOTO during follow-up. Other outcome parameters in the total cohort 
are NYHA class, permanent AF; outfl ow gradient measured with Doppler and left 
ventricular wall thickness.
Paper III
Subjects and Method 
This cohort is identical with the complete geographical cohort in Paper I and Paper 
II, consisting of 251 patients (128 males and 123 females) who fulfi lled the criteria 
of HOCM and were included in the study. As the women were older  than men at di-
agnosis (with a median difference of 11 years (p<0.001), we compared not only total 
survival but also survival by matching females and males for age at diagnosis, severity 
of cardiac hypertrophy, severity of LVOTO and treatment category (medical therapy 
only, short atrio-ventricular delay-pacing or myectomy). We identifi ed 83 pairs that 
were good matches, with mean difference in age between pairs of 0.2 (1.7) years.
Endpoints The primary endpoint was disease-related death defi ned as in Paper I and 
Paper II. Other outcome parameters in the total cohort are NYHA class, permanent 
AF; outfl ow gradient measured with Doppler and left ventricular wall thickness.
Paper IV
Subjects and Methods
This cohort is the same unselected complete geographical cohort as in Papers I, II 
and III.  Patients in myectomy-group were signifi cantly younger at procedure as com-
pared to the pacing-group. As age is expected to impact on peri-operative morbidity 
and possible return of LVOTO, we chose to compare the rates of complication and 
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morbidity also by case-control methodology, matching patients for age at interven-
tion, LVOT-gradient, maximal wall thickness, and sex if possible. We identifi ed 31 
pairs (≥18 years age at procedure) which were satisfactory matches which constituted 
the case-control group with mean difference in age between pairs of 2.6 (2.0) years 
(p=0.56). 
Clinical characteristics and ECG and ultrasound measurements were documented at 
pre-procedure, and at follow-up, in addition to peri-procedural (cardiac and non-car-
diac) complications and interventional procedures during follow-up. Complications 
were defi ned as peri-procedural when occurring during, or in the fi rst 30 days after, 
intervention.231 Cardiac and non-cardiac complications were defi ned as: any compli-
cation/re-intervention related to the procedure, perioperatively or during follow-up 
(Table 2, Paper IV). As further outcome measures the length of stay was determined, 
and the costs (material, operations- and care-related costs) during the study period 
were acquired from the National Board of Health and Welfare. 
Endpoints were peri-procedural cardiac and non-cardiac complications (within 30 
days) and re-interventions during long-term follow-up. 
Ethical considerations
The fi rst part of the study is about case note reading/archiving work, extracting data 
on patients’ clinical status, and collecting information on their medical treatment. The 
risk for the individual was considered very small even though a retrospective journal 
review always entails an integrity infringement. The benefi t for future patients was 
considered good, which justifi ed the risk to the integrity of the individual patient. Col-
lected data was coded in the database for statistics processing and no individual can be 
identifi ed in any published information. The study complies with the Declaration of 
Helsinki and was approved by local ethics committee of the University of Gothenburg 
(ÖS no 1012-12).
Statistical Methods
For all Papers (I-IV): Parameters without normal distribution are represented with 
median [interquartile range (IQR)] and normally distributed by mean ± standard de-
viation. Kolmogorov-Smirnov test has been used for assessing distribution fi tting, 
Mann-Whitney U-test for comparing the groups, Wilcoxon signed rank test for paired 
data (paired continuous variables) and Fisher’s exact and χ2 two-tailed test for com-
paring the categorical groups as appropriate. All tests were two sided, and p-values 
<0.05 were considered statistically signifi cant. Analysis was carried on SPSS software 
(version 22.0; IBM Corp., Armonk, NY, USA). For each specifi c Paper, further statis-
tical methods have been used and are described under each Paper.
Paper I: Factors infl uencing long-term heart failure mortality in patients with ob-
structive hypertrophic cardiomyopathy in Western Sweden: probable dose-related 
protection from beta-blocker therapy
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We have used Pearson’s correlation coeffi cient for continuous variables, Spearman’s 
rho for categorical data and McNemar test for comparison between paired data (paired 
binary data). Kaplan-Meier curves and log-rank test have been used for analysing of 
survival. Univariate and multivariate Cox proportional hazards method for compara-
tive analysis of risk factors for the endpoint was carried out. For multivariate analysis 
we selected variables if univariate p-values were ≤0.20. In order to have adequate sta-
tistical power the numbers of variables were restricted to six at a time in our multivari-
ate models with backward selection analysed. All tests were two sided, and p-values 
<0.05 were considered statistically signifi cant; variables with p<0.10 on multivariate 
analysis were kept in multivariate models 
Paper II: Short atrioventricular delay pacing therapy in young and old patients with 
hypertrophic obstructive cardiomyopathy: good long-term results and a low need for 
reinterventions
Box and Whisker plots were used to display the fi nal result of LVOT gradient after 
fi rst intervention. Kaplan-Meier curves and log-rank test were used for analyzing of 
survival and hazard of re-intervention.
Paper III: Factors contributing to excess female mortality in hypertrophic obstructive 
cardiomyopathy
Univariate and multivariate Cox proportional hazards method used for risk compara-
tive risk factors analyzing. Kaplan-Meier curves and log-rank test were used for sur-
vival analysis.
Paper IV: Morbidity and resource usage after myectomy- or pacing-treatment in hy-
pertrophic obstructive cardiomyopathy: a case-control study 
McNemar test was used for comparison between binary paired data and Cumulative 
hazard was analysed by Kaplan-Meier curves and log-rank test. 
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RESULTS
Paper I
Factors infl uencing long-term heart failure mortality in patients with obstructive 
hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection 
from beta-blocker therapy
Mean follow-up was 14.4±8.8 years (mean±SD) and median follow-up 13.2 
(IQR=12.4) years (Table 1, Paper I for detailed fi ndings at diagnosis). Females were 
generally older but the sex distribution was even. Beta-blocker use increased dur-
ing follow-up from 71.3% at diagnosis to 86.1% at latest follow-up (p<0.001). The 
median initial dose prescribed was 125 mg metoprolol equivalents/ day, and at latest 
follow-up was 150 mg/day for patients given BBL, with no signifi cant differences 
between intervention and non-intervention groups. Including un-treated patients the 
population median dose was 100 mg metoprolol/day. The duration of BBL treatment 
for those who had BBL since diagnosis was 13.3 [11.7] years and for patients who 
were started later it was 6.0 [3.8] years. The duration between diagnosis and introduc-
tion of BBL for those who did not have BBL since diagnosis was 4.0 [10.2] years. The 
beta-blocker dose prescribed initially had no signifi cant correlations to NYHA class, 
chest pain, syncope, outfl ow gradient or severity of cardiac hypertrophy (correlation 
coeffi cients between -0.053 and 0.144 for all). Therefore, HCM-patients with the most 
advanced disease did not obtain lower doses. 
Of 4 patients who were considered not to tolerate BBL at diagnosis 2 had BBL-therapy 
successfully started during follow-up. For more detail see Figure 4. 
Figure 4. Medication at last follow-up. BBL=Beta-blockers, CCB=Calcium-Channel 
blockers (verapamil/diltiazem).
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Verapamil/diltiazem was prescribed at diagnosis to 12.4% of patients without any 
signifi cant differences in age, arrhythmia, hypertension, LVOT ≥50 mmHg, COPD, 
angina, smoking habits or hospital affi liation (University hospital compared to local 
hospitals) compared to all patients without verapamil/diltiazem therapy. But 17.1% 
of females were given verapamil/diltiazem at diagnosis compared to 7.8% of males 
(p=0.034). Verapamil/diltiazem therapy was given in median doses of 240 (IQR=80) 
mg/day, and proportion prescribed changed only from 12.4% of patients to 12.7% at 
latest follow-up (p=0.48). For other medication see Supplementary Table S1, Paper I)
Irrespective of the type of therapy applied the New York Heart Association (NYHA) 
class was improved and the resting LVOT gradient was reduced to a median of 16 
mmHg during follow-up. However, 21% had resting gradients remaining ≥50 mmHg 
(37% in NYHA I, 37% in NYHA II, 26% in NYHA III-IV), and 33% ≥30 mmHg at 
latest follow-up (33.3% in NYHA class I, 41% in NYHA class II and 25.4% in NYHA 
class III-IV). The proportion of LVOT ≥50 mmHg was 24% in the conservative, 17% 
in pacing and myectomy groups (updated data) respectively at last follow-up. Among 
patients with LVOT gradient ≥50 mmHg at last follow-up only 7.8% had disopyra-
mide as additional medication despite AHA and ESC recommendations. The reason 
for why more active treatment was not undertaken could not be addressed from re-
cords. Atrial size and incidence of AF had increased signifi cantly at latest follow-up. 
There were 65 primary end-point events (53 cardiac deaths, 4 heart transplants and 8 
embolic deaths) during follow-up. SCD occurred in 11 (17%) patients, with an annual 
rate of 0.37% during the fi rst 10 years of follow-up as estimated only on those patients 
that received the diagnosis during the study period, Figure 5. Sixteen patients (6.4%) 
had ICD implanted (4 for secondary, 12 for primary prevention), and during follow-up 
there was only one appropriate discharge in 149 patient-years, that is an appropriate 
annual discharge rate of 0.67%.
Figure 5. Mortality in total cohort divided by HCM-related and total mortality.
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Risk factors at presentation for subsequent disease-related death
On univariate analysis, age at diagnosis, female sex, coronary artery disease and a 
resting LVOT gradient ≥50 mmHg at diagnosis were signifi cantly associated with 
endpoints (Table 2, Paper I). Verapamil/diltiazem was a risk factor on univariate, but 
not multivariate analysis. In the multivariate analysis of the whole group accepted 
initial risk factors for SCD and comorbidities were not signifi cant risk factors for total 
disease-related deaths. For multivariate analyses see Table 1.
Variable B SE Exp (B) 95% CI 
Exp (B) 
p value 
                                                             Disease-related death (93% complete data) 
Female sex 0.823 0.292 2.278 1.286-4.036 0.005 
Age  0.039 0.009 1.039 1.021-1.058 <0.001 
LVOT-gradient 50 mmHg at rest 0.631 0.301 1.879 1.042-3.388 0.036 
Metoprolol/metoprolol equivalents  dose 
mg/day
-0.004 0.002 0.996 0.992-1.000 0.028 
                                                        Heart failure death (93% complete data) 
Female sex 0.763 0.387 2.145 1.005-4.581 0.049 
Age  0.060 0.014 1.062 1.034-1.091 <0.001 
Metoprolol/metoprolol equivalents  dose 
mg/day
-0.005 0.003 0.995 0.990-1.001 0.080 
                                                        All-cause mortality (93% complete data) 
Female sex 0.805 0.252 2.237 1.367-3.663 0.001 
Age  0.050 0.008 1.051 1.035-1.068 <0.001 
LVOT-gradient 50 mmHg at rest 0.708 0.257 2.029 1.226-3.58 0.006 
Metoprolol/metoprolol equivalents  dose 
mg/day
-0.003 0.001 0.997 0.995-1.000 0.064 
Table 1. Multivariate Cox hazard analysis infl uence of initial risk factors
Predictors of disease-related death at last follow-up
On univariate Cox hazard analysis, female sex, age, NYHA class ≥III, a gradient 
remaining ≥50 mmHg and a smaller left ventricle end-diastolic diameter were associ-
ated with a signifi cantly increased risk for disease-related death (Table 3, Paper I). 
Development to dilated end stage heart failure was observed in only 4%. Verapamil/
diltiazem was a risk factor on univariate, but not multivariate analysis. Neither use of 
Disopyramide, amiodarone, ACE inhibitor nor spironolactone showed any signifi cant 
effect on survival. On multivariate model comorbidities were not independent predic-
tors. For risk factors on multivariate analysis (Table 2).
Infl uence of therapy choice on survival
Neither pacing nor myectomy reduced disease-related mortality signifi cantly see Pa-
per II.135 Verapamil therapy was associated with increased risk on univariate analysis 
(p=0.014), whereas use of beta-blocker therapy started early at diagnosis was associ-
ated with reduced risk on univariate Cox hazard analysis (p=0.004; Table 2, Paper I). 
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The association with outcome seemed to be dose-dependent with reduced risk with in-
creased daily dose (p=0.001) and dose-dependency persisted signifi cantly in the mul-
tivariate analysis (p=0.028; Table 2, Paper I), also for heart failure deaths specifi cally 
at last follow-up. The HR (Cox hazard) between early beta-blocker use and non-use of 
beta-blocker was 0.49 (95% CI 0.30 to 0.81), p=0.006. Freedom from disease-related 
deaths for patients given ≥100 mg/day metoprolol-equivalent was signifi cantly better 
than for those given 0-99 mg/day (log-rank: p=0.00004; Figure 1A, Paper I), as was 
all-cause survival, p=0.00005. Comorbidities were not signifi cantly different between 
patients in 0-99 mg/day and ≥100 mg/day groups (Supplementary Table S4, Paper I). 
The survival curves of patients with no beta-blocker initially (n=74) were overlying 
the curves of patients given 25-74 mg/day (n=36; p=0.67; online Supplementary Fig-
ure S3) and therefore these patients were combined in a 0-74 mg/day group. Survival 
curves representing three dose ranges: 0-74 mg/day, 75-149 mg/day and ≥150 mg/day 
of metoprolol-equivalents beta-blocker, the middle band including the median initial 
dose, show the advantage of larger doses of beta-blocker most obviously. There was a 
signifi cant log-rank for trend in reduced risk of disease-related deaths with increased 
dose of beta-blocker (p=0.00008; Figure 1B, Paper I and Figure 6 below). The 10-
year survival from disease-related deaths for the three dose bands, 0-74, 75-149, ≥150 
mg/day, was 83.1%, 90.7% and 97.0%, respectively. The 20-year proportions were 
Variable B SE Exp (B) 95% CI 
Exp (B) 
p value
                                                                           Disease related death  (96.8% complete data, 3.2%missing)
Female sex 1.197 0.389 3.310 1.543-7.100 0.002 
Age 0.024 0.011 1.025 1.003-1.047 0.025 
LVOT-gradient 50 mmHg at rest 1.262 0.374 3.533 1.697-7.355 0.001 
NYHA class III 0.846 0.383 2.330 1.100-4.934 0.027 
Metoprolol/metoprolol equivalents  dose 
mg/day       
-0.005 0.002 0.995 0.991-0.999 0.021 
                                                                    Heart failure death (96.8% complete data, 3.2% missing) 
Female sex 1.036 0.352 2.819 1.414-5.620 0.003 
LVOT-gradient 50 mmHg at rest 0.014 0.007 1.014 1.001-1.028 0.032 
Systemic hypertension Yes vs No 0.726 0.336 2.066 1.069-3.995 0.031 
Verapamil/Diltiazem use Yes vs No 1.036 0.414 2.817 1.251-6.343 0.012 
Metoprolol/metoprolol equivalents  dose 
mg/day 
-0.005 0.002 0.995 0.991-0.999 0.008 
                                             All-cause mortality (98% complete data)
Female sex 1.131 0.284 3.099 1.777-5.406 <0.001 
Age 0.019 0.008 1.019 1.003-1.035 0.017 
LVOT-gradient 50 mmHg at rest 0.052 0.015 1.053 1.023-1.083 <0.001 
Max wall thickness (mm) 0.071 0.030 1.074 1.013-1.139 0.017 
Metoprolol/metoprolol equivalents  dose 
mg/day 
-0.004 0.001 0.996 0.993-0.999 0.008 
Table 2. Multivariate Cox hazard analysis of predictors of disease-related death at latest follow-up
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65%, 74% and 86%, respectively. The 10-year survival from disease-related deaths 
of patients without beta-blocker therapy was 81.7%. Analysis of total mortality estab-
lished a similar shape (log-rank p-trend=0.00009), with 10-year all-cause survival of 
78.7%, 88.8% and 91.1% in respective dose bands. In the multivariate model beta-
blocker dose was associated to reduced risk for chronic heart failure and total mortal-
ity (p=0.008) at latest follow-up (Table 2).
Figure 6. Proportion of disease-related deaths belonging to each dose category 
(percent).
Beta-blockers and post-intervention gradient
Disease-related mortality was signifi cantly higher in patients who did not receive 
early BBL if residual gradient was ≥30 mmHg (10-year proportion 39.1%) than if 
gradient was <30 mmHg (10-year proportion 7.4%; p=0.002). Consequently, we ana-
lyzed if the obvious protective effect of BBL was present only in patients with a 
residual gradient of ≥30 mmHg after initial therapy. This seemed not to be the case 
as shown in Figure 2AB, Paper I.255 In this study post-intervention beta-blocker dose 
≥100 mg metoprolol/metoprolol equivalent/day was associated with signifi cantly bet-
ter survival than low dose (25-99 mg) even after interventional procedure (Figure 3, 
Paper I). There was no signifi cant difference of co-morbidity between patient groups 
(Supplementary Table S7, Paper I). In addition, there was no additional co-morbidity 
in HCM-patients who had died a disease-related death compared with survivors (Sup-
plementary Table S8, Paper I).
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According to US and European Guidelines, BBL or verapamil may be considered in 
children and asymptomatic adults with resting or provoked LVOTO, to reduce left 
ventricular pressures, but need not to be prescribed.6, 7 We investigated whether beta-
blocker therapy was associated with better survival only in symptomatic patients. We 
found that BBL were signifi cantly associated with better survival on Kaplan-Meier 
curves both in asymptomatic and symptomatic patients, Figure 7 AB.
Figure 7. A.  Beta-blockers with a median dose ≥100mg/day were associated 
to better survival in patients with all NYHA classifi cation. B. Beta-blockers with a 
median dose ≥100mg/day were associated to better survival in patients who self-
reported symptoms at diagnosis.
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In Paper I we found that verapamil/diltiazem treatment showed a signifi cant associa-
tion with increased risk of heart failure related death in univariate (p=0.008) and also 
in multivariate Cox hazard regression (p=0.012), after correction for other factors 
such as age, female gender, LVOT gradient ≥50 mmHg, systemic hypertension and 
beta-blockers (Figure 8).
Figure 8. Adjusted cumulative hazard of heart failure death at follow-up 
according to use of verapamil/diltiazem in total cohort.
Paper II
Short atrioventricular delay pacing therapy in young and old patients with 
hypertrophic obstructive cardiomyopathy: good long-term results and a 
low need for re-interventions
This study evaluates the long-term outcome after different therapies for LVOT ob-
struction. Gender distribution was even between treatment groups. However, pacing 
patients were signifi cantly older (nearly 25 years) than myectomy patients at the time 
of intervention. The initial NYHA class tended to be worse in the pacing group com-
pared with the myectomy group (p=0.05). The conservatively treated group on the 
other hand had a similar age profi le as the pacing group, but with less severe septal 
hypertrophy (p=0.031) and left atrial dilatation (p=0.001). The only difference be-
tween the patients that did not need to proceed to an intervention procedure and the 
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two interventional groups is that the group for whom medical treatment suffi ced had 
signifi cantly higher initial beta-blocker dose, median 200 mg metoprolol-equivalent 
daily versus 100 mg daily (p=0.002) (Table 1, Paper II).
Effect of therapy
Follow-up was 11.8 [9.1] years for the pacing, 10.5 [12.4] years for the myectomy and 
9.5 [9.1] years for the conservative groups respectively.
For distribution of medical therapy treatment in intervention- and non-intervention 
groups in total cohort see Figure 9.
Figure 9. Distribution of treatment in total cohort at 
last follow-up (percent).
Conservative group
For those who remained on medical therapy only, there was signifi cant improvement 
in NYHA class (p=0.006), and reduction in outfl ow-gradient to a median of 23 (43) 
mmHg (p<0.001), justifying that they did not need interventional therapy. However, 
in this group 29 (24%) had gradients ≥50 mmHg at last follow-up. Left atrial size 
increased during follow-up from 40-47 mm (p<0.001), and 40.5% had paroxysmal 
or chronical AF. The percentage receiving beta-blocker therapy increased from 73%-
88%, other medication is detailed in Figure 9. Freedom from cardiac death was 94%, 
82%, and 73% respectively (Figure 1, Paper II) at 5, 10, and 20 years in the conser-
vatively treated group, and the survival is not signifi cantly different from the two 
intervention-groups on log- rank testing (p=0.51 pacing/conservative; p=0.39 myec-
tomy/conservative). 
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Short atrioventricular delay pacing
Pacing therapy was associated with a lasting reduction in LVOT gradient to a median 
of 14 mmHg (p<0.001), a signifi cant improvement of NYHA class, and a reduction in 
septal hypertrophy. Patients had a signifi cant increase in LAD during follow-up and 
56.8% developed AF (9.1% paroxysmal and 47.7% chronic AF, updated data), which 
is a high fi gure compared to only 2 patients (0.8%) with paroxysmal AF at diagnosis. 
Re-intervention due to residual gradients during follow-up (range 50-120 mmHg) oc-
curred in 3 of 88 patients [3.4%; 1 myectomy, 2 alcohol septal ablation (ASA)]. In the 
total pacing cohort, 17% had a LVOT gradient ≥50 mmHg at last follow-up, mostly 
very elderly [median age 82 (IQR 25) years], with AF rendering constant pre-excita-
tion of the ventricle diffi cult. Annual sudden death mortality was 0.28% and annual 
cardiac mortality was 2.4% post-procedure in the pacing group, Figure 10. 
Pacing in <65 years versus ≥65 years of age 
Figure 10. Mortality outcome in total cohort.
In an earlier study it was proposed that the positive effect of pacing occurs only in 
patients >65 years of age,244 and in Table 3, Paper II and Figure 10, we therefore com-
pared the results of pacing in patients <65 years and ≥65 years at procedure. There 
were fewer females among the <65-year-olds (p=0.0028). Beta-blocker therapy ini-
tially was more common in the younger group (p=0.023), among whom BBL therapy 
increased signifi cantly during follow-up. BBL therapy increased, at last follow-up, in 
the older pacing group and the difference was no longer signifi cant compared to the 
younger group. In both age groups, there were signifi cant improvements after pac-
ing in both LVOT gradients (p<0.001 for both) and NYHA class (p<0.001 for both). 
The fi nal result for patients aged <65 years was a median gradient of 12 (20) mmHg 
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(Figure 2, Paper II), and only 9.5% had residual gradient ≥50 mmHg. Post procedural 
Kaplan-Meier curves show no differences in cardiac-mortality between myectomy 
and pacing-patients ≤65 years old at procedure, Figure 11 (log-rank p=0.60). Thus the 
treatment effect of pacing was in no way inferior in patients <65-years-olds. During 
follow-up cardiac mortality was signifi cantly lower in the younger group on log-rank 
testing (p=0.006). 
Myectomy group
The myectomy group improved the NYHA class (p=0.011), with a fi nal reduction in 
LVOT gradient (notably though in some cases only after a second re-intervention), 
to a median of 11 [16] mmHg (p=0.003) (Table 2, Paper II). Initial residual gradients 
after fi rst myectomy procedure are illustrated in Figure 2, Paper II and were 13 [45] 
mmHg compared to for pacing 14 [35] mmHg. During follow-up, 21.4% of myec-
tomy patients had a recurrence of LVOT gradient (range 60-110 mmHg) and required 
a further LVOT intervention to obtain that fi nal result (5 repeat surgery, 1 ASA, and 3 
short AV-delay pacing). At last follow-up, 14% had residual gradient ≥50 mmHg. Pos-
terior wall thickness showed a signifi cant decrease (p=0.003). Left ventricular end-
diastolic diameter (p=0.002) and left atrial size (p=0.015) increased. Beta-blocker use 
increased from 76%-83%. Annual cardiac mortality after fi rst myectomy was 2.8% 
Figure 11. Kaplan-Meier survival curves of cardiac mortality from intervention n at risk re-
fers to number of patients left in Kaplan-Meier curves.
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(Figure 10), and post-procedure annual sudden death mortality was 0.92% in total 
myectomy group. Freedom from cardiac death post-procedure at 5, 10, and 20 years 
were 93%, 93%, and 57%, respectively, in the myectomy group (log-rank pacing/
myectomy p=0.43) (Figure 1, Paper II) and survival, i.e. freedom from all-cause mor-
tality was 88%, 88%, and 51%, respectively. 
Inter-group comparisons
The conservative group had less good fi nal reduction of LVOT gradient compared 
both with the pacing group (p=0.013) and the myectomy group (p=0.003) and was the 
only group with no signifi cant reduction in hypertrophy. Disopyramide therapy was 
used more commonly in myectomy group (24%) than in pacing group (7%; p=0.016). 
Survival after time of diagnosis, which for the intervention groups is longer than post-
procedural survival, but includes survivor bias in the pre-intervention period for the 
intervention groups, was illustrated for all treatment groups (log-rank p=0.39-0.71) 
in Figure 1, Paper II and Figure 10 for outcome after intervention in interventional 
groups. For mortality outcome see Figure 10 and 11. 
We decided to focus evaluations on outcome after pacing and surgery on patients aged 
≥18 years at procedure because four of those nine requiring re-intervention after my-
ectomy had the initial procedure at age <18 years (Table 4, Paper II). A new procedure 
for recurring LVOTO occurred in 15.6% of myectomy patients and in 3.5% of pacing 
group (log-rank p=0.007). Annual post-procedural cardiac mortality was 1.3% and 
post-procedural sudden death rate was of 0.16% in pacing patients of age ≤65 years of 
age, and the fi gures was 2.2% and 0.48% in ≥18 years myectomy group. There is no 
difference in relief of LVOTO, prior to any re-intervention, between myectomy (≥18 
years) and pacing group (<65 years) (p=0.89), but the conservative group has less 
good relief (p=0.028) (Figure 2, Paper II).
Survival in patients with diagnosis before and after 2002 
Since some of our patients had their diagnoses before 2002, we ascertained if there 
were any differences in survival between those with diagnosis before and after study 
start. There was no difference among myectomy or paced patients for diagnosis be-
fore 2002 and after (log-rank p=0.53 and log-rank 0.37, respectively). The results 
also showed no inter-group difference between the groups myectomy and pacing in 
survival before 2002 (log-rank p=0.50) and after 2002 (log-rank p=0.25).
Paper III
Factors contributing to excess female mortality in hypertrophic obstructive 
cardiomyopathy
The clinical characteristics in male and female HOCM-patients were compared in the 
total cohort in Table 1, Paper III, and in the age-matched groups in Table 2, Paper III.
Follow-up time was 14.4±8.9 years (mean±SD) after diagnosis in the total cohort 
with no signifi cant difference between sexes. At diagnosis, AF was more often found 
in females, who were older but the difference did not reach statistical signifi cance in 
the age-matched group. Septal thickness, left-ventricular end-diastolic diameter and 
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left atrium diameter were signifi cantly larger in males than in females, but so was also 
body surface area, 1.8 [0.30] m² in females and 2.1 [0.25] m² in males (p<0.001).  
Bias in medical therapy
Interventional therapies (myectomy and pacing) were used without sex-bias in both 
sexes. However, males received beta-blocker therapy in a signifi cantly higher propor-
tion, 78% in males compared with 64% in females (p=0.011), the difference was con-
fi rmed in age-matched groups (80% versus 66%, p=0.040). Furthermore, the initial 
daily metoprolol-equivalents beta-blocker dose was signifi cantly lower in females, 
both in total group, and in age-matched groups (females median 50 mg/day versus 
males median 100 mg/day p<0.001), and remained signifi cantly lower even when 
corrected for body weight. In 7.8% of males and 17.1% females (p=0.034) verapamil/
diltiazem was used, and when all kinds of calcium-channel blocker therapy were in-
cluded the difference was even bigger, 19.3% and 36.1%, respectively (p=0.015), in 
the age-matched group. Disopyramide was prescribed in more males than females 
(16% versus 7%; p=0.027) during follow-up, but the difference was smaller in age-
matched group. The proportion of ICD-implantations was low in both sexes (males: 
8.6%; females 4.9%; p=0.24; 9.6% and 6.0% respectively in age-matched groups; 
p=0.39).
Clinical progress 
NYHA class improved in both sexes at follow-up (p<0.001), but the NYHA class was 
signifi cantly worse in females than males at latest follow-up, also in the age-matched 
groups (p=0.025). Deterioration of NYHA class to ≥III was 2.1 times more common 
in females than in males in both the total group (p=0.030), and in age-matched groups 
(p=0.078). Systemic hypertension (p<0.001), AF (p<0.001) and coronary artery dis-
ease (p=0.006) increased during follow-up in the same manner in both sexes in the 
age-matched groups, but the proportion of diabetes mellitus increased signifi cantly 
only in males. Median LVOT-gradients decreased signifi cantly in both sexes in the 
age-matched groups. There was no signifi cant sex-difference in patients with inad-
equate gradient control: 23% of females and 18% of males had LVOT-gradients ≥50 
mmHg at last follow-up (p=0.49). During follow-up LV ejection fraction fell signifi -
cantly in both sexes (p<0.001), Tables 1 and 2, Paper III.
 
Mortality 
Disease-related deaths occurred in 65 patients (41 in females and 24 in males). Sud-
den cardiac death occurred in 11 (17%) patients, 4 females, and 7 males. The annual 
disease-related mortality rate for the total cohort was 1.8%, with 2.4% in females and 
1.2% in males, and in the age-matched groups 2.6% versus 1.2%. Figure 1, Paper 
III, shows in Kaplan-Meier curves freedom from disease-related death comparing the 
sexes in both total and age-matched groups.
Females had a signifi cantly higher mortality risk compared to males both in total 
and age-matched groups (log-rank p=0.003; p=0.019); female-to-male HR was 2.10 
[95% CI 1.27-3.48] and 2.04 [1.11-3.76] respectively, and the shape of the total and 
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age-matched respective curves were similar. In age-matched groups 10- and 20 year 
freedom from disease-related death was 82% and 59% (female) and 93% and 85% 
(male), respectively.
Figre 12 shows the proportion of disease-related death in both sexes in total and age-
matched groups. In the total group, non-cardiac mortality was signifi cantly higher in 
females, but the same as in males in the age-matched group. The main causes of dis-
ease-related deaths are shown in Figure 2, Paper III.  Females had an excess mortality 
in heart failure with a female-to-male HR of heart failure mortality, 3.76 [95% CI 
1.85-7.66, p=0.0003] in the age-matched group, and also an excess in fatal myocardial 
infarctions, fi ve in females, and none in males (Figure 2, Paper III). Cardiac transplan-
tation was performed in three (2.4%) females and one (0.8%) male in the total cohort.
Figure 12. Proportion of disease-related death in total and age matched-groups 
(percent).
Sex-specifi c risk-factors for disease-related mortality
At diagnosis age and LVOT-gradient ≥50 mmHg in females and presence of symp-
toms in males, were signifi cant independent risk factors identifi ed by multivariate Cox 
hazard regression. Therapy with beta-blockers showed a signifi cant dose-dependent 
protective effect in the multi-variate model in males, and in univariate analysis in 
females (Table 3, Paper III).
The cardiac mortality of patients with AF at latest follow-up was non-signifi cant-
ly greater in females in the age-matched group, 44% as compared to 24% in males 
(p=0.109) (Figure 4, Paper III). The rate-control seemed possibly important for sur-
vival, where survivors in the total cohort with AF (n=51) had a heart rate at latest 
follow-up of 76 (19) beats/min, compared to non-survivors with AF (n=26) with a 
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heart rate of 87 (39) beats/min, p=0.030. Females with AF who died had heart rate of 
90 (23) versus 76 (25) in surviving females. Of those who died in chronic heart failure 
32% of females were treated with verapamil/diltiazem compared to 7.7% of males 
(p=0.0075). HR for chronic heart failure mortality with verapamil/diltiazem therapy 
was 2.26 [1.15-5.70; p=0.021] in the total cohort which included more young patients 
with low risk, and 4.20 [1.72-10.23; p=0.002], in the age matched groups. In the age-
matched groups in patients ≥50 years at latest follow-up (i.e. post-menopausal), there 
was an excess female mortality compared to males, but this was not found in patients 
<50 years of age (Figure 4, Paper III).
Effect of potentially protective pharmacotherapy on disease-related mortality
As beta-blocker treatment showed a signifi cant association with better survival in both 
sexes in univariate analysis, and in males also in multivariate analysis, we compared 
the effect of beta-blocker dose on cardiac mortality in both sexes with Kaplan-Meier 
survival curves. As males have greater body size than females, we compared sur-
vival with beta-blocker dose above and below median dose expressed as mg/kg body 
weight/day (instead of per body surface area (BSA) as there were 15% (females) and 
11% (males) missing values caused by missing information of height). The survival 
of both sexes were signifi cantly better when treated with a beta-blocker dose above or 
equal with the median of 1.18 mg/kg/day of metoprolol-equivalents compared with 
<1.18 mg/kg/day in both total group (males p=0.015, females p=0.004; Figure 5A, 
Paper III), and in age-matched groups (males p=0.007, females p=0.010; Figure 5B, 
Paper III). The curves did not separate until about seven years after diagnosis. The 
equivalent HR for disease-related deaths in total cohort with metoprolol therapy ≥1.18 
mg/kg/day were 0.32 [0.23-0.84; p=0.020] in males and 0.35 [0.16-0.73; p=0.006] 
in females. Kaplan-Meier survival analysis in age-matched groups revealed 10- and 
20-year freedom from disease-related mortality of 92% and 67% in females, and 94% 
and 94% in males in the ≥1.18 mg/kg/day groups, as compared to 75% and 51%, in 
females and 96% and 80% in males, in the <1.18 mg/kg/day groups.
Paper IV
Morbidity and resource usage after myectomy- or pacing-treatment in hy-
pertrophic obstructive cardiomyopathy: a case-control study  
This study examines complications and resource usage of pacing and myectomy when 
compared in patients with same age range and equivalent disease severity. There were 
no signifi cant differences in baseline features (Table 1, Paper IV) between matched 
groups. Left atrial diameter was signifi cantly larger in the pacing-group than in the 
myectomy-group before intervention (but the same at latest follow-up). LVOT-gra-
dient and NYHA class improved equally in both groups. Only the myectomy group 
showed a signifi cant increase in LVEDD and reduction of hypertrophy at last follow-
up. Left atrial size increased signifi cantly in both groups over time, with increasing 
prevalence of AF. The prevalence of systemic hypertension increased signifi cantly in 
both groups. Annual hospitalization for heart failure during follow-up was 0.93% in 
the pacing group compared to 2.3% in the myectomy group (p=0.21).
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Peri-procedural complications and re-interventions ≤30 days
Total study population: Peri-procedural complications were signifi cantly common af-
ter myectomy than pacing (p<0.001) (Table 2, Paper IV). One peri-operative death 
occurred among 24 fi rst myectomy procedures performed during 2002 to 2013 (3.5% 
mortality during study period). 
The case-control group: Details of peri-procedural complications are summarized in 
Table 2, Paper IV, peri-procedural complications were almost 10 times more common 
in the matched myectomy-group (p=0.001).
Late complications and re-interventions 
Total study population: Late pacemaker-implantations after more than 12 months fol-
low-up occurred in 19.5%, in three cases caused by re-interventions for recurring or 
residual LVOT-gradients (Table 2, Paper IV). A  new procedure for recurring LVOT-
gradient was required in 22.0% of patients after myectomy, and 3.4% after pacing-
therapy, p=0.001 as reported before.135
Figure 13. Late complications and re-interventions in case-control groups 
PM=Pacemaker, AVB=Atrioventricular block, LVOTO=Left ventricle outfl ow tract 
obstruction, VED=Ventricle electrode dysfunction, DVT=deep venous thrombosis. 
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Case-control-group: Pacemaker implantation (including 9.7% perioperatively) was 
required in 35.5% of myectomy patients during follow-up, 2 patients (6.5%) required 
mechanical aortic valve due to aortic insuffi ciency. The need for additional re-do for 
recurrence of LVOTO was signifi cantly higher after myectomy (16.1%) than after 
pacing-therapy (3.2%) (Figure 1A, Paper IV log-rank p=0.027). The thresholds for re-
do were the same in both groups, Paper II.135 Total re-intervention rates for all types of 
re-interventions were also signifi cantly higher in the myectomy-group (38.7% versus 
9.7%) (Figure 1B, Paper IV, p=0.003), and are summarized in Figure 13. 
Length of stay and costs of hospitalization
Median length of stay (LOS) at specialist centre was 11 [7] days for myectomy pa-
tients and 4 [IQR=2] days for pacemaker-therapy patients (p<0.001). Furthermore 
many myectomy patients had additional in-patient rehabilitation at a local hospital 
(Figure 2A, Paper IV).
The mean cost of hospitalization (local hospital costs for rehabilitation are not includ-
ed) was 74 000±16 000 SEK for pacing and 310 000±180 000 SEK for myectomy, 
p<0.001. One myectomy patient was hospitalised for 81 days because of complica-
tions after myectomy with a cost of SEK 3 million (as outlier the cost was excluded 
from our average patient costs). The average cost per myectomy procedure during 
study period nationally was SEK 200 000±70 000 (p=0.204 compared to our myec-
tomy costs, and p<0.001 compared to our pacing group costs). 
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WEAKNESSES IN OUR STUDIES
1.    Complete cohort studies are method of choice in order to be able to study risk fac-
tors for end-points but not to compare treatment effects
2.   The number of myectomy patients was small
3.    Possible loss of patients who were not registered in hospital computer systems and 
were diagnosed and monitored by private healthcare providers
4.    The Melior diagnostic patient data base was introduced in 2002. HCM patients 
who had diagnosis before 2002 and attended follow-up after 2002 became reg-
istered in the Melior data base and were included in the study, as well as two 
patients who died before 2002 but were recorded in other data bases. However, 
in the subgroup who were diagnosed before 2002 (n=160), we may have missed 
additional deaths before the study began (survivor bias). For that reason we have 
also calculated important mortality rates, such as annual risk of SCD, only in the 
patients diagnosed within the 2002-2013 period. However, the pre-2002 patients 
are important to keep in the study for the evidence they provide of the effect of 
pharmacotherapy on long-term morbidity and long-term survival.
5.    An inherent uncertainty when determining the LVOT gradient with cw Doppler 
is the possible infl uence caused by a mitral regurgitant jet. This is only a problem 
for those whose outfl ow-gradients are so large that they cannot be measured with 
PRF pulsed Doppler, and that is why we have adopted ≥50 mmHg as the cut-off 
in our risk factor analysis rather than analyzing with the gradient as a continuous 
function. It also does not affect the diagnosis classifi cation since the diagnosis is 
based on a LVOT gradient limit value ≥30 mmHg which can easily be measured 
with pulsed Doppler
6.    A moderate amount of missing data on the dose of drug (7% beta-blocker), atrial 
size (25%) / septum thickness (5.6%) / posterior wall thickness (24%) / systolic 
anterior movement (SAM) / EF (10%) at diagnosis and in 18.7% of NYHA class 
at follow-up. 
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THE STRENGTHS OF OUR STUDIES
1.    A total geographic cohort study where all patients in the Västra Götaland region 
were included regardless of age, gender and comorbidity, and this gives a popula-
tion representative patient spectrum. This is the method of choice for studying risk 
factors for adverse outcome without referral bias. 
2.   Mortality as primary endpoint (hard data)
3.    Hundred percent complete follow-up (no patients “lost to follow-up”), and with 
100% complete information on the cause of death.
4.    Large study-population consisting of 251 HOCM patients, both with the largest 
pacing group (88 patients), and the longest follow-up, both in comparison with 
other national and international published studies. It provides many patient years 
and a large number of end-points, which gives a high statistical power for analysis 
of risk- and protection factors on multivariate analysis.
5.    Long follow-up time allows us to see the effect on mortality, and unusual side 
effects, of given treatments such as any side effects of prolonged pacing in the 
HOCM group.
6.    Any measurement or documentation errors for septum, LVOT, drug use made 
by the physicians when establishing the diagnosis ought to be evenly distributed 
among the different treatment groups without affecting the outcome.
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DISCUSSION
Risk factors for disease-related death 
In this unselected geographical cohort of patients with HOCM we found that age, fe-
male sex, and an un-relieved LVOT-gradient were signifi cant risk-factors for disease-related 
mortality as they have been reported to be in studies from specialized centres.172, 193, 256-258 
However, in contrast to tertiary centres who report a SCD rate of 33-56% in HOCM-group 
with annual SCD-mortality of 0.75-1.26 %,172, 259 SCD caused a small proportion of 
disease-related deaths (17%) in our cohort with a low annual SCD-mortality of 0.37% 
despite of a low rate of ICD-implantation (6.4%). Koffl ard et al. 2003, reported 10% SCD 
during 29 years follow-up in patients with LVOTO, and 8% in non-obstructive group, with 
an annual SCD rate of 0.6% in a large community based HCM cohort of 225 patients 
(mean age 41±16 years),260 similar to our results. This may explain why classical 
risk-factors for SCD failed to show signifi cant association with total disease-related 
mortality in our cohort, in contrast to an LVOT-gradient ≥50 mmHg. In contrast to 
low fi gures, 32% of heart failure deaths reported from tertiary centres,172 heart failure 
constituted 62% of disease-related deaths in our study, similar to fi ndings in a recent 
study which demonstrated a 4.3 times excess of heart failure, and found that heart fail-
ure was more common than SCD and ventricular arrhythmia combined in population-
based HCM-patients.261 This highlights the importance of considering treatments that 
may reduce non-sudden and heart failure related mortality in HOCM patients, like a 
good control of signifi cant independent risk-factors for heart failure death in this study 
such as systemic hypertension and LVOTO. 
Effect of pharmacotherapy on risk of death
Effect of beta-blockers 
Beta-blocker therapy has hemodynamic benefi t in HCM by reducing LVOT-gradient, 
both at rest and during exercise, and by improving symptoms, diastolic function and 
exercise capacity.187, 188, 192, 262-265 In our cohort study, neither univariate nor multivariate 
Cox hazard analysis could identify that interventional therapy (myectomy or pacing) 
was associated with a survival-benefi t that was independent of other risk-factors for 
example age. But beta-blocker therapy was the only therapy associated with signifi -
cant improvement of survival in a dose-related manner on multivariate analysis (Fig-
ure 1AB, Paper I). The observation that it takes about fi ve years for survival curves 
to separate signifi cantly (Figure 1A, Paper I), suggests that the effect may be due to 
myocardial protection perhaps affecting development of fi brosis, rather than decreas-
ing SCD-mortality as reported with higher paediatric dosages.167 Frank et al. observed 
that the time to maximal improvement with medical therapy was 1-6 years (average 
2.75), suggesting at least a two years observation time is necessary to see some effect 
of medical therapy.187 In one experimental study266 in rats with diastolic dysfunction 
due to hypertension and pressure-overload, myocardial fi brosis was observed (mainly 
in the subendocardium), whereas few fi brotic changes were observed in rats with dia-
stolic dysfunction and metoprolol treatment. The degree of myocardial fi brosis was 
4.5 times greater in rats with diastolic dysfunction than in control group (p<0.001). 
Metoprolol stopped not only the progress of LV hypertrophy but also the develop-
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ment of diastolic dysfunction, and improved survival (in rats).266 A meta analysis 
with 21206 patients of the effect of beta-blockers in patients with heart failure with 
diastolic dysfunction but preserved ejection fraction (HFpEF), showed that the beta-
blocker treatment was associated with a lower risk of all-cause mortality.267 However, 
the mechanisms of the benefi t of beta-blockers on mortality have not been precisely 
clarifi ed. Ischemia is considered an important trigger for fi brosis. The rate pressure 
product is extremely closely correlated with myocardial oxygen-consumption, and 
beta-blockers reduce cardiac oxygen demand, thereby reducing ischemia during exer-
tion, and maybe, preventing or reducing  fi brosis. The signifi cant association of beta-
blocker dose to better survival even after successful interventional treatment found in 
this study is a good argument to not discontinue the treatment in patients with good 
relief of outfl ow tract obstruction after interventional procedures (Figure 3, Paper I).
According to US and European Guidelines, beta-blockers or verapamil may be con-
sidered in children and asymptomatic adults with resting or provoked LVOTO, in or-
der to reduce left ventricular pressure load.6, 7 We investigated whether beta-blockers 
were associated with better survival only in symptomatic patients but we found that 
the association to better survival was as good in patients without symptom at diagno-
sis (Figure 7AB). 
Could the protective effect of beta-blockers in Paper I be due to a chance association? 
That the protective effect of beta-blocker on survival found in Paper I is not a chance 
fi nding is supported by the extremely strong signifi cance on Kaplan-Meier survival 
analysis (p=0.0004-0.0008), and the fact that beta-blocker protection is dose-related, 
and remains signifi cant on Cox hazard analysis together with all other identifi ed risk 
factors (Paper I). It is also supported by other reports of survival benefi t of beta- 
blocker therapy in HCM. In childhood HCM beta-blocker therapy is also associated 
with improved survival,95 in a dose-related manner,4, 96, 167 and even reduces risk of 
SCD.167 Beta-blocker is associated with better survival in HFpEF patients with other 
diagnoses causing diastolic dysfunction as well.267
There are no randomized long-time beta-blockade studies on mortality in adult HCM-
patients. Of the registry studies available, Melacini et al.’s negative study from 2007 
is often cited, but in that study, only 26% of patients (77/293; 456 patient years) were 
treated with beta-blockers, with a median follow-up of 6 years, and the authors only 
studied effect on sudden cardiac death. The study had only 17 (10%) end-points and 
lacked statistical power to detect a protective effect of beta-blockers because only 
about 1/4 of the patients received beta-blockers.109 In contrast, Lee et al. (2007) found 
in univariate analysis in a study of 163 patients followed on average 5.3 years, of 
whom 40% received beta-blockers, that beta-blocker use (dose not stated) had a sig-
nifi cant protective effect with a HR of 0.25 [95% CI0.08-0.77], p=0.012; the effect did 
not remain signifi cant in a seven-parameter multivariate analysis,193 but their statisti-
cal power would be insuffi cient to test that many parameters in the same multivari-
ate analysis. Recently, in a much larger study focusing on gender differences (3673 
patients), Geske JB et al. (2017) has shown in his multivariate analysis that beta-
blocking therapy (dose unspecifi ed) was associated with a lower total mortality,268 but 
they could not distinguish heart-related mortality from non-cardiac mortality. With 
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our study with 2613 patient-years on beta-blocker therapy and with 100% follow-up255 
there are now three studies from adult patient cohorts of very different ethnic origin, 
and several from British and Swedish separate childhood cohorts, that report statisti-
cally signifi cant survival benefi t from beta-blocker use. The HR for patients with beta-
blocker use from diagnosis in our cohort study was 0.49 [95% CI 0.30-0.81] (Paper 
I). The fact that the association was dose-dependent, (Figure 1AB, Paper I), suggests 
a pharmacological effect and not a chance association.
Could the protective effect of beta-blockers in Paper I be a result of bias in treatment 
selection? 
We have included all patients in the complete geographical cohort and have a long 
follow-up time (14.4±8.9) years, with no patients lost to follow-up, and no selection 
or referral bias. There are no signifi cant differences in co-morbidity that could be 
confounders between the various treatment groups. There is a slight gender bias for 
women being given lower beta-blocker doses than men (Paper III), but the protective 
effect of beta-blocker therapy is signifi cant both in men and women (Paper III), and 
remains signifi cant on multi-variate Cox hazard analysis including both age and sex as 
co-factors in the analysis (Paper I). Thus we cannot fi nd evidence of the result being 
affected by bias in any known risk factor. 
Hypothetical mechanisms for benefi t of beta-blockers on  pathogenesis of hypertrophy 
in HCM  
There is animal experimental evidence that increased cardiac sympathetic activity 
is an important trigger of compensatory both generalized and localized cardiac hy-
pertrophy.49 Generalized cardiac hypertrophy results from physical exercise269, 270 and 
from beta-agonist administration (isoprenaline).271, 272 The compensatory left ventricu-
lar hypertrophy due to experimental coarctation of the aorta273 and right ventricular 
hypertrophy due to hypoxia,274 can both be reduced or prevented with non-selective 
and beta1-selective beta-adrenoceptor blockade.
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Beta-adreno-receptor blocking drugs have been reported to decrease cardiac hypertro-
phy, e.g. in experimental renal hypertension,275 in spontaneously hypertensive rats,276,  277 and 
in systemic hypertension in man.278, 279 Conversely, vasodilator therapy that normal-
izes the systemic blood pressure and at the same time increases cardiac sympathetic 
nervous activity, is not associated with regression, but often with progression, of car-
diac hypertrophy in the spontaneously hypertensive rat.280, 281 As detailed in introduc-
tion there are many studies reporting pathologically increased cardiac sympathetic 
nervous activity in HCM-patients,91-94 and it is a reasonable hypothesis that modifying 
this pathophysiology may be of benefi t. For example, regarding HCM in children and 
adolescents, retrospective well-matched cohort studies showed that untreated HCM 
patients had a 24-26% increase in left ventricular hypertrophy over follow-up, where-
as patients who had been on high-dose beta-blocker therapy because of symptoms 
(>4.5 mg propranolol/kg BW) instead showed a reduction in cardiac hypertrophy by 
20-28%.282 As maximal wall thickness is an important risk factor for SCD,6, 7 a ben-
efi cial effect on disease-progression may partly explain the dose-related reduction in 
the risk of sudden arrhythmia observed in childhood HCM.4, 96, 167 However, a reduced 
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progression of hypertrophy may also hypothetically reduce the risk of progressive 
fi brosis and deteriorating function.
Calcium blocker therapy
Harmful acute effects of verapamil have been reported before and it has to be used 
with caution.194, 283, 284 The observed long-term excess mortality in heart failure in 
HOCM-patients getting verapamil/diltiazem in our studies (Paper I and Paper III) is 
concerning but should be interpreted with caution due to the small numbers receiv-
ing calcium-channel blockers. This underlines that more studies in HCM-populations 
with greater use of calcium-channel blockers than in our study are needed.
Effect of invasive treatment on clinical outcome and mortality in HOCM 
patients
Short AV-delay pacing 
In Paper II, which is the biggest one hitherto with longest follow-up time, we showed 
that pacing improved NYHA class and reduced LVOT gradient signifi cantly (Table 
2, Paper II). Pacing was not inferior to myectomy on disease-related mortality on 
Kaplan-Meier curves (Figure I, Paper II, p=0.71, Figure 11 <65 years age pacing vs 
myectomy), and had the same result on LVOT gradients in patient <65 years-old com-
pared to ≥65-years-old (Figure 2, Paper II). Pacing had a signifi cantly lower risk for 
re-intervention and peri-procedure complications than myectomy (Table 2, Paper IV). 
Even in matched groups the cumulative hazard for re-intervention for LVOTO or any 
other re-intervention during follow-up was signifi cantly lower than after myectomy 
(Paper IV, Table 2 and Figure 1AB). Pacing patients had signifi cantly shorter stay in 
hospital and substantially lower costs compared to myectomy (Paper IV, Figure 2AB). 
Myectomy patients received signifi cantly higher disopyramide use (24%) compared 
to pacing (7%) (p=0.016), and some cases needed a second intervention to achieve the 
same LVOT gradient at latest follow-up. 
In DDD pacing with short AV-delay for pre-excitation of the left ventricle the place-
ment of pacing electrode to stimulate the right ventricular apex for achieving complete 
ventricular capture is important for the treatment result.218-221, 223, 235-237 Observational 
short-term studies with short AV-delay pacing from the USA and Europe showed good 
symptom improvement and LVOT gradient reduction with pacing.235, 237, 241 Signifi cant 
benefi t was confi rmed in a European multi-centre randomized cross-over study with 
83 patients.222,  240,  285 Some of the symptom benefi t may be a placebo-effect,286 but ac-
tive short AV-delay pacing reduced gradient signifi cantly more than sham-pacing.222 
The improvement of symptoms and reduction of LVOTO is not persistent after cessa-
tion of pacing, re-initialization of pacing promptly reduces the LVOTO and improves 
symptoms to a preexisting extent.287 In two small American randomized crossover 
studies (patients n=21-48), with short follow-up time (6-36 months) compared DDD 
versus AAI pacing. The outcomes measured were the size of LVOT gradient, quality 
of life, exercise tolerance and Peak V02. The result showed that active pacing was 
associated with improvement of LVOTO within 3 months with progressive improve-
ment over the next 9 months, accompanied with improvements in quality of life and 
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or NYHA class in majority of patients. The larger American randomized double-blind 
cross-over study (Multicenter Study of Pacing Therapy for Hypertrophic Cardiomy-
opathy (MPATHY) of 48 patients confi rmed signifi cant benefi t of pacing treatment to 
outfl ow gradient and quality of life, but found no signifi cant improvement in exercise 
ability.3 This study had 16 (33%) of patients lost to follow-up, and medication was 
reduced during the study in a non-standard manner. In the end, 3/32 (9.4%) of the re-
maining patients were without cardio-protective medications, and it is not clear from 
the study how much of the drug doses had been reduced in the remaining patients. In 
addition the MPATHY authors in retrospect defi ned a responder as the combination 
of improvement >1 NYHA class, >10% exercise time and >10 points in the Minne-
sota Living with heart failure score. By this strict and also limiting defi nition only 6 
of 48 randomized patients were responders to active pacing. In this study responders 
were signifi cantly older (mean age 69±4 years) than non-responders (mean age 51±16 
years) and had a lower initial exercise time (9.7±3.4 min) and Peak VO2 (12.4 mL/
kg/min) than non-responders (17.1±5.5 mL/kg/min), p<0.0005. Based on those small 
numbers the authors therefore suggested that DDD pacing could be an option for 
patients >65 years of age if they reject other treatment options244 but the result of our 
study showed that pacing is equally effective for patients <65 years old (n=44) as for 
patients ≥65 years old (n=44) (Paper II, Table 3). 
Another small non-randomized study compared 20 patients treated with myectomy, 
based on patient preference, with 19 patients treated by short AV-delay pacing.243 In 
this study, signifi cantly better gradient reduction and greater improvement in exercise 
capacity were reported in the myectomy group than in the pacing group. The follow-
up time in the study, however, was longer for myectomy than patients with pacing 
therapy, myectomy patients were on average 17 years younger, many sick patients 
undergoing myectomy were not included in the study (selection bias), and in addition 
patients who underwent DDD pacing under study time (1995-1997) were part of a 
multicenter randomized trial as mentioned above (M-PATHY) with a LVOT gradient 
reduction by 40% in M-PATHY study.244 However, the same cohort of patients as in 
M-PATHY in this study had a LVOT gradient reduction by 29%, thus a 25% smaller 
reduction than in M-PATHY (also suggesting selection bias), all this may be relevant 
for their ability to increase exercise capacity and the result of this study. These two 
studies243, 244 were probably infl uential in that short AV-delay pacing was removed 
from considerations as a fi rst choice in the American Heart Association (AHA) guide-
lines for HOCM treatment. 
More recently positive long-term results have been reported from non-randomized 
retrospective studies of pacing.245, 246 Our results are in concordance with results from 
these studies regarding the improvement of symptoms and reduction of LVOT gradi-
ent. Lucon et al.246 reported on 51 patients treated with pacing at an average age of 
59 years, with follow-up of 11.5 years, with survival rates at 5 and 10 years of 90% 
and 65%, respectively. Thus, our total pacing cohort of 88 patients is by far the largest 
till now reported in the literature with very long-term results after pacing treatment. 
Similar to Lucon et al.246 the total survival, including non-cardiac mortality, in our 
pacing group was 91%, and 70% for survival at 5 and 10 years. In addition to mortal-
ity we report also the morbidity, and cost of procedure with length of stay in hospital 
which is not reported in a systematic way before. The European Guidelines from the 
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European Society of Cardiology 2014 recommends pacing to patients who are elderly, 
at high risk when undergoing septal reduction, patients who do not want to undergo 
surgery and those who have a mild hypertrophy.7 However there is a now new interest 
in pacing.238, 288 In a recent meta-analysis of 34 studies comprising 1135 patients with 
short AV-delay pacing Arnold et al. reported that pacing reduced gradient by 35% 
(p< 0.0001) in 4 short blinded randomized controlled trials (RCTs), but there was only 
a trend towards improved NYHA class (p= 0.066). The un-blinded observational stud-
ies reported a 54.3% (p< 0.0001) reduction in gradient and signifi cant improvement in 
NYHA class (p< 0.0001). Since those studies had much longer follow-up the results 
could well be due to progressive gradient reduction over time with benefi cial remodel-
ing. Through all studies, the LVOT gradient gradually decreased at longer follow-up 
durations, by 5.2% per month.288 In these times of increasing fi nancial pressures on 
health services we feel that the comparatively very low cost, good success rate and 
very low morbidity of short AV-delay pacing could justify it being adopted as a fi rst-
line therapy for drug resistant obstructive HCM.
Myectomy 
Surgical myectomy at tertiary centers has been the gold standard treatment for most 
patients with severe drug-refractory symptoms since 1964 with a reduction of LVOT 
gradient in 90% of patients when performed in expert centres.6, 21, 225-227
The long-term result of myectomy in our cohort study showed a signifi cant clinical 
improvement and LVOT gradient reduction at follow-up (Paper II). To achieve this 
reduction of LVOT gradient a signifi cant larger proportion (24%) of myectomy pa-
tients had disopyramide compared to pacing-group (7%), p=0.016, following a strat-
egy for advanced treatment of HOCM patients as advocated by Sherrid et al.,190 and a 
signifi cant proportion underwent a second re-intervention and myectomy group had 
signifi cantly longer stay at hospital and much higher costs compared to our pacing 
group (Paper IV).
The total pooled peri-procedural complication-rate after myectomy in our total myec-
tomy group (31%), and in matched myectomy-group (35.5%), Table 2, Paper IV, was 
comparable to other reports (28%-30.2%).232, 233 One peri-operative death occurred 
among 24 fi rst myectomy procedures performed during study period 2002-2013 
(3.5% annual mortality) in line with audited operative mortality of 3.8% reported by 
Kim et al.233 from highest volume tertile myectomy centres in the USA (four hospitals 
with 126 myectomy during nine years of study period), but substantially higher than 
the self-reported fi gures of 0.3-1.1% from the same centers.228, 289 
Among postoperative cardiac complications (<30 days) after myectomy 7.2% of our 
patients in the total myectomy-group were implanted with a pacemaker for total AV-
block after fi rst myectomy. This rate was greater than reports from dedicated Ameri-
can HCM-centres (1%)227 or from Mayo clinic of 2%,234 but in line with reports from 
a national US registry data that showed the audited incidence of pacemaker-implanta-
tion was actually 8.9% for this high-volume tertile, as compared to 10% in the tertile 
with lowest volume of myectomies.233 In total 26.7% of the total myectomy-group in 
our total cohort needed a pacemaker during follow-up, almost equal to the 25.8% in 
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the case-control group. This high need for pacemaker implantation after myectomy 
during late follow-up has not been reported before. There was only a 4.1% need for 
pacing on long-term follow-up even in much older patients treated only medically, 
comparable to the rate of 4.4% reported in literature.290 Thus our 100% complete and 
signifi cantly longer follow-up, and recording also all types of late re-intervention not 
only surgical ones, can partly explain why we fi nd a relatively high need for pace-
maker-implantation and also of re-do, after myectomy, compared to previous reports 
from tertiary centres. In our total myctomy group 22% required re-do for recurrence 
of LVOT gradient during 12.9 years of follow-up, but re-do rates was slightly lower in 
non-growing patients, being 15.6%, in patients ≥18 years at myectomy. However, all 
but one re-intervention occurred more than 1 year after the fi rst myectomy. Surgical 
re-intervention for LVOTO after myectomy at Cleveland Clinic, excluding patients 
<18 years of age, and >65 years at surgery, was 3.4% over an 8.7 year follow-up289 as 
in our pacing group but less than in our myectomy patients, however non-surgical re-
interventions were not reported. Our result presented as freedom from cardiac deaths 
at 10 years follow-up of 93%, and total survival at 10 years of 88%, are comparable 
to the high volume tertiary centers with patients of comparable age at myectomy like 
Mayo clinic (96% survival),291 the Stanford clinic (81% survival),5 and a Swiss group 
(80% survival)292 at 10 years. In contrast to our study with 100% follow-up and report 
on re-intervention (Paper IV, Table 2 and Figure 1AB) those studies had 11-14% of 
patients lost to follow-up with unknown survival status and did not report re-interven-
tion rates. 
The LOS in hospital for myectomy in our study was a median of 11 days similar to 
that reported by others,231, 232 with a mean costs of 310 000±180 000 SEK for each 
myectomy comparable to American reported costs.232 The similar cost was 74 000± 
16 000 SEK in our pacing-group. In this regards pacing has signifi cantly shorter dura-
tion of stay and signifi cantly lower cost compared to myectomy for drug refractory 
HOCM patients (Paper IV, Figure 2AB).
Short AV-delay pacing continued to be widely used in Europe, at least until the in-
creasing acceptance of ASA as an alternative treatment option for symptomatic 
LVOTO.224, 293 ASA has recently been used to a greater extent in Europe as it is alleged 
that it has an effect as good as myectom y,7 but there are no randomized studies. ASA 
has a higher frequency of complications in the form of atrio-ventricular blocks requir-
ing permanent pacemaker following the procedure (7-20%)7 compared to myectomy 
(4%).249 ASA has 10% re-do rate for LVOTO250, 259 and in this study re-do after pacing 
is 3.5%. Quintana et al. reported that patients who are referred to myectomy after ASA 
with insuffi cient relief of LVOTO have poorer diastolic function and higher frequency 
of arrhythmias, a higher frequency of postoperative complete heart block and a higher 
perioperative mortality rate of 6.2%.251 In our study pacing, with no mortality, few 
complications, cost effective, a smaller need for redo (3.5%) and not inferior to my-
ectomy regarding re-intervention and survival, might be considered as fi rst option for 
drug refractory HOCM patients. We believe that it is not justifi ed to virtually abandon 
it as a fi rst-line therapy option as has been done in the 2011 AHA guidelines.6
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The best way to settle the rightful place of short AV-delay pacing among the treatment 
options would be a prospective-randomzed study comparing pacing with ASA, and 
of suffi ciently long duration that the continued fall of gradient over the fi rst two years 
that has been amply documented in pacing patients is allowed to register.
Gender
Is it a “risk factor” to be a woman, or is the risk for disease-related death 
underestimated in women?
In this total geographical cohort study females had excess HCM-related mortality compared 
to men (Paper I),255 (Paper III, Figure 1), also reported from tertiary centres.118, 257, 258, 268 
However, the factors causing the increased mortality in females have not been established. 
In all published sex-comparisons of mortality HCM females are signifi cantly older 
than males at diagnosis118, 255, 257, 258, 268  making comparisons of mortality uncertain be-
cause of  signifi cant differences in non-cardiac mortality between, females and males 
(non-age matched), shown in our study (Paper III, Figure 2). Delay in establishing 
diagnosis has been speculated on as cause of the excess mortality.258, 268 The excess 
female mortality in groups matched for age at diagnosis and other clinical features 
showed in this study, suggests that referral-bias or age differences at diagnosis is not 
the probable cause of the reported excess female death in HCM patients.
The main criterion for making the diagnosis of HCM in both AHA and ESC guide-
lines is a maximal wall thickness ≥15 mm (or ≥13 mm in the presence of an affected 
fi rst-degree relative).6, 7 This immediately presents a sex-bias, since the upper limit 
of LV wall thickness is normally 1 mm lower in adult females than in males at all 
ages.294, 295 Accordingly, to meet the requirements for the HCM diagnosis a woman 
has to show up to 17% larger increase in cardiac wall thickness in relation to normal 
values than men. This can postpone the diagnosis to somewhat later in the disease 
development, and might be a factor in the reported age-related gender-difference in 
disease penetrance.296, 297 This could be avoided by implementing sex-independent 
hypertrophy criteria by using M-mode echocardiographic wall-to-cavity ratios, for 
making the diagnosis. This method is sex-independent with the same normal range in 
males and females, and was originally studied to simplify the diagnosis of HCM, or 
following development of hypertrophy, in the growing child/adolescent.298, 299 Another 
possibility is to measure LV remodeling index by using CMR, dividing LV mass by 
end-diastolic volume,300 or by the use of CMR wall-to-cavity ratios.301 
Sex-differences in LV-remodeling and fi brosis between age-matched HCM-patients, 
with a higher LV-remodeling index and greater extent of late gadolinium enhancement 
(LGE) in women compared to men, are proposed to be a cause for severity of disease-
expression in females.300, 302  In our study patients had no difference in NYHA class at 
the time of diagnosis, but whereas a majority improved NYHA class with treatment, 
twice as many women as men showed the opposite and worsened to NYHA class 
≥III, also in age-matched group (Paper III, Tables 1 and 2), similar to two tertiary 
center results.257, 268 Regarding hormonal infl uence, our data (Paper III, Figure 4) from 
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an unselected geographical cohort, agrees with fi ndings by Olivotto et al.257 that the 
excess mortality occurs in post-menopausal age, in contrast to a study from a Chinese 
tertiary centre.258 
Possible causes of excess female mortality 
A larger LVOT-gradient increases the risk for death and clinical deterioration.303 Nei-
ther in our total geographical cohort nor in age-matched group were there any signifi -
cant differences in resting LVOT-gradients between males and females at diagnosis 
(Paper III, Tables 1 and 2) despite contrary reports from several tertiary centre stud-
ies.258, 268 
The reason for the contrasting results one can only speculate. Is there a higher threshold 
for referral to a tertiary centre for women, particularly in China? The fi ndings in our geo-
graphical cohort however shows that the observed impaired prognosis among females 
could not be explained by differences in resting LVOT-gradients at diagnosis between 
men and women. It is notable however, that among our patients with an initial LVOT-
gradient ≥50 mmHg females had 37% and males 22% mortality during later follow-up 
(p=0.004). According to this fi nding one has to refl ect if the differences in pharmaco-
logical treatment between the sexes found could be relevant for the poorer outcome 
in women. Signifi cantly fewer females were given beta-blocker therapy initially, 66% 
versus 80% among age-matched patients, and the initial dose used was smaller even 
adjusting for body size. 
It is notable that a lower proportion of women were given beta-blockers, with a medi-
an dose of only 50 mg/day in metoprolol-equivalents after diagnosis, despite women 
being more symptomatic (76%), and 44% versus 34% in men complained about chest 
pain. This observation is in line with another study in Australia (ischemic study) re-
porting more active treatment in men, as angiography was around 25% higher among 
men, and PCI/CABG in men were around 150% higher than in women.304 Similar 
reports with less active treatment of women for acute coronary syndrome are reported 
from the USA305 and Sweden.306 Our fi ndings suggesting a protective effect of beta-
blockers have been discussed in section above. Beta-blocker therapy has been reported 
to reduce risk of death in both children and adult patients with HCM 95, 167, 255, 268  but it 
is worth to re-emphasize that  the protective effect is dose-dependent in multi-variate 
analysis167, 255 including sex as a variable (Paper I).255 The protective effect of higher 
than median doses of beta-blockers (≥1.18 mg/kg/day in metoprolol-equivalents) was 
present in both sexes (Paper III, Figure 5AB), and we observed that in the age-matched 
groups, female 10-year survival was much closer to that of males in the ≥1.18 mg/
kg/day group (92% versus 94%). The survival with doses of ≥150 mg metoprolol-
equivalents/day was even better (97% 10-year freedom from disease-related death 
when both sexes combined, log-rank for trend p=0.00008 (Paper I, Figure 1B).255 
In this study females with AF had a tendency to a poorer prognosis than males with 
AF at last follow-up, with disease-related death of 44% compared to 24% (Paper III, 
Figure 4, p=0.109). A theoretical explanation is that the females, perhaps with im-
paired diastolic function, had not as good rate-control of their AF during physical ac-
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tivity as males, because of lower prescribed beta-blocker doses. Beta-blocker therapy 
has been shown to reduce compensatory cardiac hypertrophy in animal models,49 and 
to reduce cardiac fi brosis and myofi bre degeneration by 67-91% in spontaneously 
hypertensive rats,307 so it is not unreasonable to hypothesize that beta-blocker therapy 
could infl uence disease development positively and reduce progress of fi brosis also 
in human HOCM,  mainly in patients with sub-optimal control of outfl ow-gradients 
leading to subendocardial ischaemia on activity. Disopyramide therapy is also sig-
nifi cantly underused in females, 7% versus 16% in males (p=0.027). A signifi cant 
additional disease-related mortality in the age-matched group occurred specifi cally in 
myocardial infarctions among women (Paper III, Figure 2), also reported by others.305 
That calcium-channel blocker therapy was signifi cantly more common in the female 
group might be a potential factor in the excess mortality, especially in chronic heart 
failure seen in females, and multi-variate analysis in the total cohort revealed that 
verapamil/diltiazem therapy was a signifi cant risk factor for heart failure deaths (Pa-
per I).255 Our group of calcium-blocker treated patients is quite small, so the harmful 
effect of verapamil/diltiazem on heart failure related mortality showed in this study 
has to be interpreted with caution.
Reducing the delay in diagnosis in females, using effective beta-blocker and diso-
pyramide therapy early to control LVOT-gradients adequately even in asymptomatic 
patients, and increasing physician awareness that women have a higher propensity for 
diastolic dysfunction than men might be associated with improvement of prognosis in 
women. Furthermore, early recognition and management of atherosclerosis and other 
co-morbidities might be helpful in reducing mortality in females with HCM.
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CONCLUSIONS
In this unselected geographical cohort we found that heart failure was a dominant 
cause of death in HOCM, and showed that female sex, age and persisting LVOT 
obstruction were important independent risk factors for disease-related, and specifi -
cally heart failure-related deaths. The data indicate that beta-blocker therapy would be 
benefi cial even in asymptomatic LVOT obstruction, aiming for doses of at least 150 
mg/day metoprolol equivalents. 
Short AV-delay pacing as a simple, cost-effective procedure was not inferior to myec-
tomy in the relief of LVOTO. Furthermore, pacing therapy was associated with a low 
need for perioperative complications and later re-interventions. Our data support the 
view that short AV-delay pacing should be considered a valid option to treat patients 
with HOCM, and the comparatively low costs suggests that, while we await results 
of randomized prospective comparisons with alcohol septal ablation, it merits consid-
eration as fi rst choice option on cost-benefi t criteria, particularly in countries with a 
population size that mean that surgical volumes for myectomy will remain low even 
if centralized to one centre.
Greater efforts at early diagnosis in females, and a more liberal, and earlier, use of 
beta-blocker therapy and disopyramide to optimize gradient-control and diastolic 
function, might improve outcome in females with HCM.
Generally it can be commented that a signifi cant proportion of HOCM patients do 
not receive appropriate escalation of therapy according to international guidelines 
even when substantial outfl ow gradients remain. Despite their worse prognosis female 
were especially likely to receive inadequate treatment. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING
Bakgrund 
Hypertrofi sk kardiomyopati (HCM) är en ärftlig hjärtmuskelsjukdom som drabbar 
0,2% av befolkningen. Hjärtmuskeln är förtjockad, vanligtvis i vänster hjärtkammare. 
Av dessa har ca en fjärdedel en extra förtjockning belägen i vänster hjärtkammares 
utfl ödesdel som ger upphov till en förträngning (”obstruktion”). Man talar om hyper-
trof obstruktiv kardiomyopati (HOCM). Utfl ödeshindret innebär att hjärtat blir mer 
ansträngt när det skall pumpa ut blodet i kroppspulsådern. Det uppstår en skillnad 
i blodtrycket mellan hjärtkammaren och kroppspulsådern (”utfl ödesgradient”). En 
minsta tryckskillnad om 30 mmHg krävs för HOCM-diagnos men det kan bli mer än 
100 mmHg.  
Symptomen kan antingen vara obetydliga eller uttalade med andfåddhet och ben-
svullnad, bröstsmärta, blodpropp i hjärnan eller till och med dödliga rytmrubbningar. 
HOCM anses ligga bakom stor proportion av dödsfall hos unga idrottsutövare.
Prognosen vid HOCM som handlagts i rutinsjukvård är ofullständigt känd. De fl esta 
undersökningarna kommer från högspecialiserade centra som tar hand om de sjukaste 
patienterna.
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Behandlingen syftar till att minska utfl ödesgradienten. Många patienter blir förbätt-
rade av mediciner, men en stor grupp kräver ytterligare behandling för att må bra. 
Man kan då med viss pacemakerbehandling åstadkomma god lindring. Om man med 
en pacemakerimpuls startar kontraktionen långt nere i kammaren vänder man på för-
loppet och kammaren kan till stor del tömma sig innan ringmuskeln blivit fullständigt 
sammandragen. Goda resultat kan man också få med en hjärtoperation där man tar 
bort en del av den muskel som bildar ett hinder för hjärtkammaren att tömma sig. 
Detta ingrepp ”myektomi” är förstahandsrekommendation i alla internationella rikt-
linjer. Pacemakerbehandling är accepterad i de europeiska riktlinjerna, men förbigås 
i de amerikanska. Orsaken härtill torde vara att det endast fi nns ett fåtal uppföljande 
studier av pacemakerbehandling vid HOCM och att de har få patienter med kort upp-
följningstid.
Ett litet antal patienter blir så svårt sjuka att de måste genomgå hjärttransplantation.
Avhandlingens syfte har varit att via långtidsuppföljning kunna jämföra effekterna 
av de olika behandlingsmetoderna i en oselekterad kohort som handlagts i svensk 
allmänsjukvård.
Via diagnosregistren vid samtliga västsvenska sjukhus under tiden 2002-2013 iden-
tifi erade vi 251 patienter med HOCM: av dessa behövde 121 enbart mediciner, 88 
erhöll pacemakerbehandling och 42 genomgick hjärtoperation med myektomi.
Under en uppföljningstid om 14 år avled 65 patienter vilka analyserats närmare. Klart 
ökad risk för död förelåg om höggradigt utfl ödeshinder kvarstod. Trots att kvinnorna 
erhöll pacemaker eller hjärtoperation i samma omfattning som männen var risken 
för död fyra gånger högre och berodde på hjärtsvikt och hjärtinfarkter. Den samlade 
risken för att avlida var densamma oavsett om patienten fi ck pacemaker eller hjärto-
peration. 
Ungefär var tredje opererad patient drabbades av komplikationer vid ingreppet eller 
under uppföljningen jämfört med 3.2% vid pacemakerbehandling.
Mest uppmuntrande är resultaten av tablettbehandling med betablockare. En dos me-
toprolol om minst 100 mg/dag minskar risken för död, lägre dos har tveksam effekt 
och kan delförklara den ökade dödligheten för kvinnor eftersom kvinnor fi ck beta-
blockerarbehandling i lägre dos än män även korrigerat för kroppsstorlek. Positivt var 
också att majoriteten av patienterna fi ck bättre ork av alla behandlingsformer.
Huvudbudskapet blir att hjärtsvikt var huvudorsaken till dödsfallen. Risken för att av-
lida skilde sig inte åt mellan de olika behandlingarna, men risken är starkt avhängig av 
en tillräckligt hög dos betablockare. Här fi nns en klar förbättringspotential vad gäller 
medicinsk behandling av kvinnor. Pacemakerbehandlingen är effektiv och skonsam 
och medför betydligt lägre kostnader än myektomi. Den borde kunna komma till ökad 
användning som första alternativ för de som inte svarar på medicinsk behandling. 
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